


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:40Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406335" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406335</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>redoxrep</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Redox Rep</journal-id><journal-id journal-id-type="iso-abbrev">Redox Rep</journal-id><journal-id journal-id-type="pmc-domain-id">3660</journal-id><journal-id journal-id-type="pmc-domain">redoxrep</journal-id><journal-title-group><journal-title>Redox Report : Communications in Free Radical Research</journal-title></journal-title-group><issn pub-type="ppub">1351-0002</issn><issn pub-type="epub">1743-2928</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406335</article-id><article-id pub-id-type="pmcid-ver">PMC12406335.1</article-id><article-id pub-id-type="pmcaid">12406335</article-id><article-id pub-id-type="pmcaiid">12406335</article-id><article-id pub-id-type="pmid">40897326</article-id><article-id pub-id-type="doi">10.1080/13510002.2025.2550807</article-id><article-id pub-id-type="publisher-id">2550807</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Cytochrome P450 (CYP) 1 enzymes in acute lung injury: from molecular insights to therapeutic implications</article-title><alt-title alt-title-type="right-running-head">REDOX REPORT</alt-title><alt-title alt-title-type="left-running-head">Y. YOU ET AL.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>You</surname><given-names initials="Y">Yiting</given-names></name><role vocab="credit" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft">Writing &#8211; original draft</role><role vocab="credit" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing">Writing &#8211; review &amp; editing</role><xref rid="AF1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="J">Jingqian</given-names></name><role vocab="credit" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis">Formal analysis</role><role vocab="credit" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/" vocab-identifier="https://credit.niso.org/" vocab-term="Software">Software</role><xref rid="AF2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="X">Xiaoyan</given-names></name><role vocab="credit" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition">Funding acquisition</role><role vocab="credit" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision">Supervision</role><xref rid="AF2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sheng</surname><given-names initials="H">Hui</given-names></name><role vocab="credit" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision">Supervision</role><role vocab="credit" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing">Writing &#8211; review &amp; editing</role><xref rid="AF2" ref-type="aff">b</xref><xref rid="cor2" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yujian</given-names></name><role vocab="credit" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition">Funding acquisition</role><role vocab="credit" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision">Supervision</role><role vocab="credit" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/" vocab-identifier="https://credit.niso.org/" vocab-term="Validation">Validation</role><xref rid="AF1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp"/></contrib><aff id="AF1"><label>a</label>School of Kinesiology, The Key Laboratory of Exercise and Health Sciences of Ministry of Education, <institution>Shanghai University of Sport</institution>, <city>Shanghai</city>, <country>People&#8217;s Republic of China</country></aff><aff id="AF2"><label>b</label>Department of Physiology, <institution>Naval Medical University</institution>, <city>Shanghai</city>, <country>People&#8217;s Republic of China</country></aff></contrib-group><author-notes><corresp id="cor1"><label>CONTACT</label> Yujian Liu <email xlink:href="liuyujian@sus.edu.cn">liuyujian@sus.edu.cn</email> School of Kinesiology, The Key Laboratory of Exercise and Health Sciences of Ministry of Education, <institution>Shanghai University of Sport</institution>, <addr-line>200 Hengren Road</addr-line>, <city>Shanghai</city><postal-code>200438</postal-code>, <country>People&#8217;s Republic of China</country></corresp><corresp id="cor2">Hui Sheng <email xlink:href="huisheng7979@126.com">huisheng7979@126.com</email> Department of Physiology, <institution>Naval Medical University</institution>, <addr-line>800 Xiangyin Rd</addr-line>, <city>Shanghai</city><postal-code>200433</postal-code>, <country>People&#8217;s Republic of China</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>30</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">478716</issue-id><elocation-id seq="47">2550807</elocation-id><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event><event event-type="tagger"><event-desc>Nova techset</event-desc><date><day>21</day><month>8</month><year>2025</year></date></event><event event-type="build-issue-online"><event-desc>Converted to JATS 1.2 by Nova Techset</event-desc><date><day>21</day><month>8</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="YRER_30_2550807.pdf"/><self-uri content-type="pdf" xlink:href="YRER_30_2550807.pdf"/><abstract><title>ABSTRACT</title><sec><title>Objective:</title><p>This review aims to explore the roles and mechanisms of cytochrome P450 subfamily 1 (CYP1) enzymes in acute lung injury (ALI), and to discuss their potential as therapeutic targets.</p></sec><sec><title>Methods:</title><p>A comprehensive literature search was conducted using PubMed and Web of Science to identify relevant studies on the involvement of CYP1 enzymes&#8212;specifically CYP1A and CYP1B1&#8212;in various forms of ALI, including hyperoxic lung injury, sepsis-associated ALI, and COVID-19 pneumonia.</p></sec><sec><title>Results:</title><p>CYP1 enzymes, induced by the aromatic hydrocarbon receptor (AhR), contribute differentially to ALI. CYP1A enzymes exhibit protective effects, whereas CYP1B1 promotes lung injury, potentially through oxidative stress-related pathways such as Nrf2, NF-&#954;B, and MAPK signaling.</p></sec><sec><title>Conclusion:</title><p>The distinct functions of CYP1 isoforms in ALI suggest their clinical relevance, highlighting the potential for isoform-specific targeting in the treatment of acute respiratory conditions.</p></sec></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Cytochrome p450(CYP) enzymes</kwd><kwd>acute lung injury</kwd><kwd>oxidative stress</kwd><kwd>inflammation</kwd><kwd>clinical application</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>China National Natural Science Foundation</institution></institution-wrap></funding-source><award-id>32171124</award-id><award-id>81971780</award-id><award-id>32271180</award-id><award-id>32471185</award-id></award-group><award-group><funding-source><institution-wrap><institution>Naval Medical University</institution></institution-wrap></funding-source><award-id>JCXYXZ-001</award-id></award-group><funding-statement>This research was funded by the China National Natural Science Foundation (Nos. 32171124, 81971780, 32271180, 32471185), Fund of the Basic Medical College, Naval Medical University (No. JCXYXZ-001).</funding-statement></funding-group></support-group><counts><fig-count count="4"/><table-count count="3"/><equation-count count="0"/><ref-count count="106"/><page-count count="18"/><word-count count="6938"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec disp-level="1" id="S001"><title>Highlights</title><p>
<list list-type="bullet"><list-item><p>This review provides the first systematic analysis of CYP1A's protective versus CYP1B1's harmful effects in ALI through NRF2, NF&#954;B and MAPK pathways.</p></list-item><list-item><p>It highlights a crucial research gap &#8211; while animal and cellular studies demonstrate CYP1 isoforms&#8217; mechanisms, human clinical validation remains lacking.</p></list-item><list-item><p>It proposes novel clinical translation strategies including placenta-targeted AhR agonist delivery for preterm infants and exercise interventions to combat age-related CYP1 decline.</p></list-item></list>
</p></sec><sec disp-level="1" id="S002"><label>1.</label><title>Introduction</title><p>Cytochrome P450 (CYP) enzymes belong to a class of heme protein superfamily with monooxygenase activity. In human genes, the CYP family is divided into 18 families and 44 subfamilies [<xref rid="CIT0001" ref-type="bibr">1</xref>]. More than 95% of oxidation and reduction reactions are catalyzed by the CYP family [<xref rid="CIT0002" ref-type="bibr">2</xref>]. It should be emphasized that CYPs catalyze monooxygenation reactions, introducing one oxygen atom into a substrate molecule to form a hydroxyl group. This group is important because it facilitates reactions with other molecules. Endogenous substrates of the CYP family include arachidonic acids, estradiol, arachidonic acid, cholesterol, vitamin D, and some neurotransmitters [<xref rid="CIT0003" ref-type="bibr">3</xref>]. Critically, CYP enzymes mediate the synthesis and metabolism of all steroid hormones. In addition, in exogenous metabolism, some CYP enzymes regulate the oxidation of exogenic compounds such as drugs and environmental pollutants. Thus, CYP enzymes are significant for many physiological processes and drug efficacy evaluation.</p><p>The CYP1 family is a branch of the CYP family, including CYP1A and CYP1B1 subfamilies [<xref rid="CIT0002" ref-type="bibr">2</xref>]. The CYP1A subfamily includes two isoforms, the CYP1A1 and 1A2 enzymes [<xref rid="CIT0002" ref-type="bibr">2</xref>]. CYP1A1 enzyme is mainly found in extrahepatic tissues, such as the pancreas, thymus, uterus, placenta, small intestine, lung, and kidney [<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0005" ref-type="bibr">5</xref>], whereas the CYP1A2 enzyme is mainly expressed in the liver, gastrointestinal tract, and brain [<xref rid="CIT0006" ref-type="bibr">6</xref>,<xref rid="CIT0007" ref-type="bibr">7</xref>]. Moreover, CYP1B1 enzyme is mainly expressed in vascular endothelial cells, breast, prostate, and uterus, and a small amount in renal, intestinal, and brain [<xref rid="CIT0008" ref-type="bibr">8&#8211;10</xref>]. As biocatalysts, the CYP1 family can metabolize some endogenous and exogenous compounds depending on the REDOX equivalent of the electronic form for biotransformation [<xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0011" ref-type="bibr">11</xref>].</p><p>Transcription of the CYP1A1, CYP1A2, and CYP1B1 enzymes is regulated by the aromatic hydrocarbon receptor (AhR) [<xref rid="CIT0012" ref-type="bibr">12-14</xref>]. AhR is a ligand-activated transcription factor that is predominantly cytoplasmic and highly expressed in human lung, thymus, kidney and liver [<xref rid="CIT0015" ref-type="bibr">15</xref>]. The classical AhR signaling pathway consists of four main steps: cytoplasmic complex formation, AhR transport to the nucleus, AhR heterodimerisation and induction of CYP1 enzyme expression.</p><p>In recent years, the CYP1 family has been shown to play an important role in various acute lung injuries, supported by a large number of studies in cell culture, animal models and clinical research. This review highlights the roles and mechanisms of CYP1 enzymes in acute lung injury.</p></sec><sec disp-level="1" id="S003"><label>2.</label><title>Metabolism of CYP1 enzymes</title><sec disp-level="2" id="S003-S2001"><label>2.1</label><title>Enzymatic oxidative metabolic reaction</title><p>The CYP1 family belongs to the CYP family and acts as a biocatalyst. Over 95% of oxidation and reduction reactions are catalyzed by CYP enzymes [<xref rid="CIT0002" ref-type="bibr">2</xref>]. These enzymes can perform a wide range of reactions, but the most common is the oxidation of the substrate (R). Critically, CYP enzymes catalyze monooxygenation reactions wherein one oxygen atom is introduced into a substrate molecule to form a hydroxyl group (&#8211;OH), enabling subsequent reactions with biomolecules.</p><p>The general reaction mechanism is [<xref rid="CIT0016" ref-type="bibr">16</xref>] :RH&#8201;+&#8201;2H<sup>+</sup>&#8201;+&#8201;O<sub>2</sub>&#8201;+&#8201;2e<sup>-</sup> &#8594; ROH&#8201;+&#8201;H<sub>2</sub>O. Assuming that RH represents the drug, the iron ion on the pre-reaction cytochrome p450 is present in the form of ferric (Fe<sup>3+</sup>). Step 1: At the beginning of the reaction, the drug binds before the enzyme. Step 2: The drug and enzyme complex is reduced by NADPH, which is oxidized to NAD<sup>+</sup>, transferring electrons to the drug enzyme complex, and ferric (Fe<sup>3+</sup>) is reduced to ferrous (Fe<sup>2+</sup>). Step 3:O<sub>2</sub> enters and combines with ferrous (Fe<sup>2+</sup>). Step 4: NADPH is oxidized to NAD<sup>+</sup>, which transfers electrons to the drug enzyme complex and activates oxygen. Step 5: Two H<sup>+</sup> come in and react with the complex, and two electrons from the oxygen transfer to the two protons to form one molecule of H<sub>2</sub>O. Then oxygen atoms (O) are transferred to the drug, which is oxidized. The enzyme releases the metabolite ROH produced in this process, and the CYP returns to its original state, ready for the next round of catalytic reactions. Reaction cycle of knowledge in understanding how CYP1 enzyme resisting oxidative stress plays an important role.</p></sec><sec disp-level="2" id="S003-S2002"><label>2.2</label><title>Hormone</title><p>The CYP1A1, CYP1A2 and CYP1B1 enzymes play a key role in hormone metabolism and are involved in the metabolism of estrogens, arachidonic acid and melatonin. With regard to estrogen metabolism, the CYP1A2 enzyme is the predominant enzyme in the liver that catalyzes the conversion of estradiol to 2-hydroxyestradiol, whereas the CYP1A1 enzyme performs an analogous function in extrahepatic tissues [<xref rid="CIT0017" ref-type="bibr">17</xref>]. In target tissues for estrogen such as the breasts, ovaries, and uterus, CYP1B1 enzyme significantly contributes by specifically catalyzing the 4-hydroxylation of estradiol [<xref rid="CIT0017" ref-type="bibr">17</xref>]. It is worth noting that, not only estradiol but all steroid hormones are synthesized and metabolized by CYPs. In the metabolism of arachidonic acid, CYP1A1 enzyme, CYP1A2 enzyme, and CYP1B1 enzyme are responsible for producing 75% of hydroxyeicosatetraenoic acids (HETEs), 52% of epoxyeicosatrienoic acids (EETs), and 54% of mid-chain HETEs [<xref rid="CIT0018" ref-type="bibr">18</xref>]. These metabolites play a critical role in inflammation and cellular signaling [<xref rid="CIT0018" ref-type="bibr">18</xref>]. Furthermore, CYP1 enzymes are involved in the metabolism of melatonin through a 6-hydroxylation process, which directly impacts the nervous system and visual functions [<xref rid="CIT0019" ref-type="bibr">19</xref>]. The activity and expression patterns of these enzymes are essential for maintaining hormonal balance and related physiological functions (<xref rid="F0001" ref-type="fig">Figure 1</xref>).
<fig position="float" id="F0001" orientation="portrait"><label>Figure 1.</label><caption><p>The CYP1A1, CYP1A2 and CYP1B1 enzymes play a key role in hormone metabolism. A:oestrogens; B:arachidonic; C: acid and melatonin.</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="YRER_A_2550807_F0001_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="YRER_A_2550807_F0001_PB.jpg"/></alternatives></fig></p></sec><sec disp-level="2" id="S003-S2003"><label>2.3.</label><title>Medicinal drugs</title><p>Cytochrome P450 (CYP) is a major source of variability in drug pharmacokinetics and responses. Among the 57 presumed functional human CYPs, only about 12 enzymes, belonging to the CYP1, 2, and 3 families, are responsible for the biotransformation of most xenobiotics, including 70-80% of clinically used drugs [<xref rid="CIT0001" ref-type="bibr">1</xref>].</p><p>Particularly, CYP1A1, as a key enzyme, is capable of activating a variety of prodrugs into active compounds with significant therapeutic effects. It activates Aminoflavone, producing metabolites that have an inhibitory effect on cancer cells [<xref rid="CIT0020" ref-type="bibr">20</xref>]. In addition, drugs metabolized by CYP1A1 include dacarbazine [<xref rid="CIT0021" ref-type="bibr">21</xref>], procarbazine [<xref rid="CIT0022" ref-type="bibr">22</xref>], flutamide [<xref rid="CIT0022" ref-type="bibr">22</xref>], and iCT2700 [<xref rid="CIT0023" ref-type="bibr">23</xref>].</p><p>Similar to CYP1A1 enzyme, CYP1A2 enzyme is an extremely important drug-metabolizing enzyme in the liver, participating in the metabolism of about 9% of clinically used drugs. The types of drugs metabolized by CYP1A2 enzyme are extensive, including propranolol, duloxetine, acetaminophen, phenacetin, lidocaine, olanzapine, and clozapine [<xref rid="CIT0001" ref-type="bibr">1</xref>, <xref rid="CIT0007" ref-type="bibr">7</xref>].</p><p>In the field of cancer treatment, the overexpression of CYP1B1 is associated with resistance to a variety of chemotherapeutic drugs. The excessive expression of this enzyme in cancer cells may lead to increased resistance to chemotherapeutic agents such as cisplatin [<xref rid="CIT0024" ref-type="bibr">24</xref>], paclitaxel [<xref rid="CIT0025" ref-type="bibr">25</xref>], docetaxel [<xref rid="CIT0024" ref-type="bibr">24</xref>], flutamide [<xref rid="CIT0026" ref-type="bibr">26</xref>], mitomycin [<xref rid="CIT0027" ref-type="bibr">27</xref>], tamoxifen [<xref rid="CIT0028" ref-type="bibr">28</xref>], and doxorubicin [<xref rid="CIT0029" ref-type="bibr">29</xref>]. This highlights the complex role of CYP enzymes in the response to cancer treatment and their significance in drug metabolism (<xref rid="F0002" ref-type="fig">Figure 2</xref>).
<fig position="float" id="F0002" orientation="portrait"><label>Figure 2.</label><caption><p>CYP1 family enzymes participate in oxidation and reduction reactions in vivo, with a typical reaction process: RH&#8201;+&#8201;2H<sup>+</sup>&#8201;+&#8201;O<sub>2</sub>&#8201;+&#8201;2e- &#8594; ROH&#8201;+&#8201;H<sub>2</sub>O. In addition, CYP1 enzymes are also involved in the metabolic processes of substances such as estrogen, arachidonic acid, and melatonin. Most of the biotransformation processes of exogenous drugs depend on the action of CYP1 enzyme.</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="YRER_A_2550807_F0002_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="YRER_A_2550807_F0002_PB.jpg"/></alternatives></fig></p></sec></sec><sec disp-level="1" id="S004"><label>3.</label><title>CYP1 enzymes and acute lung injury</title><sec disp-level="2" id="S004-S2001"><label>3.1</label><title>Hyperoxic lung injury</title><p>Hyperoxic lung injury is commonly seen in patients who require supplemental oxygen for underlying lung disease and is characterized by increased alveolar capillary permeability, increased lung weight and loss of ventilated lung tissue [<xref rid="CIT0030" ref-type="bibr">30</xref>]. CYP1A enzymes have been shown to protect against hyperoxic lung injury, while inhibition of CYP1A enzymes can induce lung injury under high oxygen exposure [<xref rid="CIT0031" ref-type="bibr">31</xref>]. The inducers of CYP1A enzymes, such as b-naphthalene flavone (BNF), quercetin, and omeprazole, can increase CYP1A enzymes expression in hyperoxic conditions, therefore have similar effects to CYP1A enzymes on the lung. For example, prenatal BNF treatment protects newborn offspring mice from oxygen-mediated lung injury. And administration of BNF in CYP1A knockout mice that are more susceptible to oxygen-mediated lung injury, induces the expression of CYP1A enzymes and NQO1 enzymes in the lung, as well as improves alveolar simplification, increases the radial alveolar count (RAC), and decreases the Mean Linear Intercept length, demonstrating the protective effect of BNF in lung function [<xref rid="CIT0008" ref-type="bibr">8</xref>, <xref rid="CIT0032" ref-type="bibr">32</xref>]. Moreover, quercetin elevates the expression of CYP1A1/CYP1A2/NQO1 enzymes in the lung and liver under hyperoxic conditions, then reduces the levels of malondialdehyde protein adduct and neutrophil, and then inhibits macrophage infiltration, which attenuates hyperoxia-mediated lung injury [<xref rid="CIT0033" ref-type="bibr">33</xref>]. Omeprazole can reduce pulmonary edema, perivascular and alveolar damage by increasing the expression of CYP1A1 and CYP1A2 enzymes [<xref rid="CIT0034" ref-type="bibr">34</xref>]. In addition, the study by JIANG et al. have demonstrated that hyperoxia activates the human CYP1A1-Luc promoter in newborn mice and induces endogenous mouse CYP1A1 gene expression in the liver and lungs of CYP1A1-Luc mice, thus reducing lung damage in mice [<xref rid="CIT0035" ref-type="bibr">35</xref>]. However, adult mice carrying human CYP1A1-Luc or mouse CYP1A2-Luc were more susceptible to lung injury than wild-type (WT) mice, possibly because of reduced endogenous expression of CYP1A enzymes induced by chronic hyperoxia [<xref rid="CIT0036" ref-type="bibr">36</xref>]. The above studies suggest that the CYP1A enzymes play a protective role in hyperoxic lung injury.</p><p>Unlike CYP1A enzymes, CYP1B1 enzymes may promote hyperoxia-induced lung injury. In the human bronchial epithelial cell line BEAS-2B, overexpression of CYP1B1 enzymes aggravates hyperoxia-induced cytotoxicity, while CYP1B1 siRNA decreases cell death and preserves cell viability after exposure to hyperoxia [<xref rid="CIT0037" ref-type="bibr">37</xref>]. Consistently, the knockout of CYP1B1 gene in lung endothelial cells significantly reduces hyperoxia-mediated apoptosis [<xref rid="CIT0037" ref-type="bibr">37</xref>]. Moreover, Smerdova et al. demonstrated that CYP1B1 enzymes catalyze the metabolism of polycyclic aromatic hydrocarbons, which might contribute to enhanced bioactivation and genotoxic effects under the condition of inflammations [<xref rid="CIT0038" ref-type="bibr">38</xref>]. THAKUR et al. have suggested that PAHs induce the activity of enzymes such as CYP1B1, promoting their own metabolic activation, resulting in the production of active metabolites that can bind to DNA, which may ultimately lead to the development of cancer [<xref rid="CIT0039" ref-type="bibr">39</xref>]. Additionally, it has been found that significantly upregulated CYP1B1 protein levels in the neonatal lungs, accompanied by pulmonary edema and alveolar bleeding in the newborn exposed to hyperoxia for several days [<xref rid="CIT0039" ref-type="bibr">39</xref>]. Interestingly, data from Gene Set Enrichment Analysis data has shown that 118 pathways related to hyperoxia are downregulated in CYP1B1 gene deletion mice after hyperoxia exposure, including lipid, glutamate, and amino acid metabolism pathways [<xref rid="CIT0040" ref-type="bibr">40</xref>], which also supports that CYP1B1 may be involved in hyperoxia-induced lung injury.</p></sec><sec disp-level="2" id="S004-S2002"><label>3.2</label><title>Sepsis</title><p>An increasing number of studies have reported that CYP1A enzymes are associated with acute lung injury caused by severe sepsis. As exposure to lipopolysaccharide (LPS) is a well-known model of sepsis, it can mimic sepsis-associated acute lung injury and endothelial barrier dysfunction [<xref rid="CIT0007" ref-type="bibr">7</xref>]. TIAN et al. demonstrated that LPS induces a significant increase in CYP1A1 enzymes in some tissues, such as the lung, liver, and kidney, which is independent of aromatic hydrocarbon receptors (AhR) [<xref rid="CIT0041" ref-type="bibr">41</xref>]. And CYP1A1 knockout aggravates pulmonary edema, neutrophil infiltration, and alveolar structural destruction, which is induced by LPS-activated inflammation [<xref rid="CIT0041" ref-type="bibr">41</xref>]. In the LPS-induced pulmonary inflammation model, the reduced activity of the CYP1A1 enzyme leads to a decrease in the lung's detoxification capacity for BaP, allowing more BaP to enter the bloodstream and distribute to extrapulmonary organs, such as the liver, resulting in increased levels of BaP-DNA adducts in these organs [<xref rid="CIT0042" ref-type="bibr">42</xref>]. The decrease in CYP1A1 activity is a key factor in how pulmonary inflammation affects the genotoxicity of PAHs, suggesting that pulmonary inflammation may control the genotoxicity of PAHs by regulating CYP1A1 activity.</p><p>In addition, CYP1A1 enzyme was found to be highly expressed in the lungs, liver, and kidney of mice treated with LPS, CYP1A1 knockout mice exhibit pulmonary edema, neutrophil infiltration, and alveolar structural destruction, which may be related to activation of inflammatory responses in the lung, suggesting that decreased CYP1A1 enzyme may enhance LPS-induced acute lung injury [<xref rid="CIT0041" ref-type="bibr">41</xref>]. Notably, similar to CYP1A1 enzymes, CYP1A2 enzyme also plays a protective role in lung injury induced by sepsis. Some studies demonstrated that cecal ligation and puncture (CLP)-induced sepsis rats show down-regulated CYP1A2 enzyme levels and translocation of AhR from cytoplasm to nucleus. Moreover, it has been reported that inhibition of CYP1A2 enzymes decreases inflammatory cytokines levels, such as TNF-&#945;, IL-1&#946;, and IL-6 in the serum, and improves the survival rate of mice with sepsis [<xref rid="CIT0043" ref-type="bibr">43</xref>]. In conclusion, the CYP1A enzymes have protective effects on acute lung injury in some types of sepsis.</p><p>Few studies have focus on the effect of CYP1B1 enzyme on sepsis-associated acute lung injury. Stading et al. have found that the activator of CYP1B1 enzymes PAH exposure prenatally leads to lung damage in neonatal mice exposed to hyperoxia, with higher radial alveolar counts and lower mean linear intercept in lung tissue from mice lacking the CYP1B1 gene [<xref rid="CIT0044" ref-type="bibr">44</xref>]. By bioinformatic analysis of four transcriptome datasets from the GEO database, it has been found that there are significant differences in CYP1B1 gene in blood between sepsis and non-sepsis diseases [<xref rid="CIT0045" ref-type="bibr">45</xref>], with upregulated CYP1B1 enzyme expression in sepsis samples. Consistent with this result, HAO et al. also found that CYP1B1 enzyme was highly expressed in immune cells of septic subjects in clinical trials [<xref rid="CIT0046" ref-type="bibr">46</xref>]. Additionally, the results from single-cell RNA sequencing have shown that CYP1B1 enzymes may influence the function of basal cells, macrophages, and interstitial cells [<xref rid="CIT0047" ref-type="bibr">47</xref>], which plays an important role in lung injury in sepsis models.</p></sec><sec disp-level="2" id="S004-S2003"><label>3.3</label><title>COVID pneumonia</title><p>COVID pneumonia is a lung infection caused by SARS CoV-2. Recent studies have shown that two variants of the CYP1A1 gene, rs2606345, and rs1048943, are associated with the risk of COVID pneumonia, in this study, there is a positive correlation between the &#8216;A&#8217; allele frequency of the CYP1A1 SNP (rs2606345) with COVID-19 prevalence in populations worldwide [<xref rid="CIT0048" ref-type="bibr">48</xref>]. Given that COVID-19 enters the body through angiotensin converting enzyme-2 (ACE2) receptors [<xref rid="CIT0049" ref-type="bibr">49</xref>]. A recent in vitro study has demonstrated that AhR agonists such as CSE, FICZ, and OMP can inhibit the expression of ACE2 in mammalian cells, which may affect the infection process of SARS-CoV-2, as ACE2 is a key receptor for the virus to enter host cells [<xref rid="CIT0050" ref-type="bibr">50</xref>]. Especially in HepG2 cells treated with CSE, the expression of ACE2 significantly decreased while the expression of CYP1A1 increased, showing a negative correlation between the expression of ACE2 and the AHR target gene CYP1A [<xref rid="CIT0050" ref-type="bibr">50</xref>]. This suggests that AHR activation may affect the level of ACE2 by regulating the expression of CYP1A1, and may thereby inhibit the internalization and infection efficiency of SARS-CoV-2. In addition, CYP1A1 enzyme exhibits hydroxylase activity in the oxidation of arachidonic acid (AA), therefore promoting the conversion of hydroxy-eicosanotetraenoic acid (HETEs) [<xref rid="CIT0005" ref-type="bibr">5</xref>], which plays a protective role in lung injury through its vasodilator effect [<xref rid="CIT0051" ref-type="bibr">51</xref>]. Exogenous supplementation of AA in the HCoV-229E infected cells significantly inhibits the replication of the HCoV-229E virus [<xref rid="CIT0052" ref-type="bibr">52</xref>]. These findings suggest that CYP1A1 enzymes may have a protective effect on COVID pneumonia.</p><p>In vitro studies of liver cells have shown that some inflammatory factors, such as IL-1, IL-6, IFN-&#947;, and TNF-&#945;, can inhibit CYP1A2 enzymes during viral infection [<xref rid="CIT0053" ref-type="bibr">53</xref>]. Severe COVID-19 patients are often accompanied by cytokine storms, with high expressions of IL-2, IL-4, IL-6, TNF-&#945;, and IFN-&#947; [<xref rid="CIT0054" ref-type="bibr">54</xref>]. However, there is no data on the effects of other CYP enzymes in the lung during novel coronavirus infection.</p></sec><sec disp-level="2" id="S004-S2004"><label>3.4</label><title>Bacterial pneumonia</title><p>Pseudomonas aeruginosa (PA) and methicillin-resistant Staphylococcus aureus (MRSA) are common pathogens causing severe pneumonia and acute respiratory distress syndrome (ARDS) [<xref rid="CIT0055" ref-type="bibr">55</xref>, <xref rid="CIT0056" ref-type="bibr">56</xref>]. In pulmonary endothelial cells (ECs), CYP1A1 exhibits dual roles: basal expression supports normal lung function, while pathogen-induced overexpression exacerbates inflammatory injury. Specifically, MRSA epigenetically upregulates endothelial CYP1A1 through histone H3 lysine 9 acetylation (H3K9ac) and aryl hydrocarbon receptor (AhR) activation, thereby increasing vascular permeability and pro-inflammatory cytokine release, ultimately driving endothelial barrier dysfunction and acute lung injury [<xref rid="CIT0056" ref-type="bibr">56</xref>]. PA may indirectly induce CYP1A1 via AhR activation by bacterial pigments [<xref rid="CIT0057" ref-type="bibr">57</xref>, <xref rid="CIT0058" ref-type="bibr">58</xref>]. Thus, CYP1A1 acts as a context-dependent mediator &#8211; pathogen-triggered induction aggravates bacterial sepsis, whereas constitutive activity mitigates oxidative or endotoxin-mediated damage,such as hyperoxia and LPS models [<xref rid="CIT0031" ref-type="bibr">31</xref>, <xref rid="CIT0041" ref-type="bibr">41</xref>]. Therapeutic targeting must preserve cytoprotective functions while suppressing pathological overexpression.</p><p>Notably, while CYP1A1 promotes MRSA-induced EC inflammation, its precise mechanistic contributions remain undefined. Current literature on CYP1A1/1A2 mechanisms in bacterial lung injury is sparse (PubMed/Web of Science queries); thus, this study focuses on established roles in hyperoxia and LPS-induced lung injury.</p></sec></sec><sec disp-level="1" id="S005"><label>4.</label><title>Potential mechanisms underlying CYP1 enzymes in acute lung injury</title><p>As mentioned above, CYP1 enzymes have been implicated in acute lung injury caused by various diseases. Some studies have demonstrated that CYP1A enzymes may contribute to the clearance of harmful substances, inhibition of inflammatory reactions, and alleviation of oxidative stress, thereby reducing the severity of lung injury. However, the role of CYP1B1 enzymes appears to be opposite to that of CYP1A enzymes. Moreover, CYP1B1 enzyme is considered to be responsible for the metabolism of many important physiological compounds, including estrogen, arachidonic acid, and melatonin [<xref rid="CIT0008" ref-type="bibr">8</xref>], then in turn produces reactive oxygen species and activates inflammatory responses, therefore plays a key role in the pathogenesis of acute lung injury [<xref rid="CIT0059" ref-type="bibr">59</xref>]. CYP1 enzymes play an important role in acute lung injury caused by a variety of diseases. However, its potential mechanisms are complicated, which may be involved in some key signaling molecules, such as NF-&#954;B, MAPK, and NRF2, etc (<xref rid="F0003" ref-type="fig">Figure 3</xref>).
<fig position="float" id="F0003" orientation="portrait"><label>Figure 3.</label><caption><p>CYP1 enzymes play a key role in acute lung injury caused by a variety of diseases, including sepsis, hyperoxic lung injury, and COVID pneumonia. AhR is regulated through various pathways, such as medicinal drugs, environmental pollutants, flavonoids and compounds exercise, which affect the expression of CYP1 enzymes. CYP1 enzymes may regulate the expression of NRF2, NF-&#954;B, and MAPK and other key signaling molecules. In acute lung injury, CYP1A1 and CYP1A2 enzymes play a protective role, while CYP1B1 enzyme has the opposite effect.</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="YRER_A_2550807_F0003_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="YRER_A_2550807_F0003_PB.jpg"/></alternatives></fig></p><sec disp-level="2" id="S005-S2001"><label>4.1</label><title>NF-&#954;B</title><p>NF-&#954;B is an important mediator of the cellular response to inflammation and oxidative stress. Some studies have shown that AhR has &#8216;crosstalk&#8217; with NF-&#954;B signaling pathway. Baglole et al. recently reported that AHR plays a critical role in limiting inflammatory responses by maintaining the expression of RelB to restrict the production of pro-inflammatory COX-2 and PGs, and this action is independent of the classical activation pathway of NF-&#954;B [<xref rid="CIT0060" ref-type="bibr">60</xref>]. A recent study also found an interaction between AhR and NF-kB under hyperoxic conditions, with increased NF-kB activity in AhR-deficient (AhRd) mice exposed to hyperoxia [<xref rid="CIT0061" ref-type="bibr">61</xref>]. In addition, in AhR-deficient fetal human lung microvascular endothelial cells (HPMEC), hyperoxia exposure results in decreased RelB activation, which is a component of the NF-&#954;B protein that contributes to anti-inflammatory processes, and the cells are more prone to oxidative stress, inflammation, and cell death [<xref rid="CIT0062" ref-type="bibr">62</xref>]. In human dendritic cells (DC), LPS increases AhR-induced CYP1A1 enzyme expression through the NF-&#954;B signaling pathway [<xref rid="CIT0063" ref-type="bibr">63</xref>]. In summary, AhR interacts with the NF-&#954;B signaling pathway, and together they participate in the cellular response to inflammation and oxidative stress by regulating the expression of RelB and the activity of the antioxidant enzyme CYP1A1 enzyme.</p><p>It has been demonstrated that postnatal antioxidant quercetin treatment induces the expression of CYP1A1 and CYP1A2 enzymes while suppressing NF-&#954;B protein expression, which is beneficial for reducing lung inflammation [<xref rid="CIT0033" ref-type="bibr">33</xref>]. In vitro experiments have shown that omeprazole hyperoxia activates AhR, inducing the expression of Phase I and Phase II detoxifying enzymes such as CYP1A1 enzymes, which downregulate NF&#954;B, thereby attenuating the cytotoxicity of human lung adenocarcinoma epithelial cell line H441 [<xref rid="CIT0064" ref-type="bibr">64</xref>]. NF-&#954;B has also been found to inhibit AhR-mediated CYP1A1 enzyme expression in mouse hepatocellular carcinoma cells (Hepa1c1c7) [<xref rid="CIT0065" ref-type="bibr">65</xref>]. Tian et al. have found that in LPS-induced acute lung injury (ALI), the knockout of CYP1A1 increases the activation of NF-&#954;B. Treatment with the NF&#954;B inhibitor pyrrolidine dithiocarbamate (PDTC) reverses the pro-inflammatory response induced by CYP1A1 knockout. These studies suggest that CYP1A1 enzymes may promote the activation of NF-&#954;B, thereby aggravating LPS-induced acute lung injury [<xref rid="CIT0041" ref-type="bibr">41</xref>]. In addition, the NF-&#954;B inhibitor PDTC has been shown to partially interdict CYP1A2 enzyme activity with reduced inflammation [<xref rid="CIT0066" ref-type="bibr">66-68</xref>].</p><p>In contrast, Yang et al. showed that activation of NF-&#954;B protects neonatal lungs from acute hyperoxic damage by increasing anti-inflammatory and anti-apoptotic genes [<xref rid="CIT0069" ref-type="bibr">69</xref>]. Interestingly, Lingappan et al. found that hyperoxia leads to higher expression of CYP1A1, therefore inducing higher expression of NF-&#954;B p65 in the lung of neonatal female mice than those of neonatal male ones, which may partly explain why newborn male mice are more susceptible to oxygen-mediated lung injury and alveolar simplification in the hyperoxic environment [<xref rid="CIT0070" ref-type="bibr">70</xref>].</p><p>In general, NF-&#954;B activates pro-inflammatory genes and increases inflammation, however, the downstream effects of NF-&#954;B activation are regulated by the subunit composition of the complex. The consensus sequence for NF-&#954;B is found in genes that respond to oxidative stress, inflammation, and apoptosis. Five members of the immediate NF-&#954;B family have benn identified: NF-&#954;B1 (p50), NF-&#954;B2 (p52), p65/RelA, RelB, and cRel. Previous studies have shown that p50 homodimers suppress LPS-mediated transcription of TNF-&#945; [<xref rid="CIT0071" ref-type="bibr">71</xref>, <xref rid="CIT0072" ref-type="bibr">72</xref>]. In summary, the balance between pro-inflammatory and anti-inflammatory effects may determine whether NF-&#954;B activation is protective or harmful. NF-&#954;B plays a complex role in inflammation, activating inflammatory responses and, under certain conditions, inhibiting inflammation as well, depending on the specific subunit composition of the NF-&#954;B complex and the cellular environment. Therefore, in acute lung injury, the activation of the NF-&#954;B signaling pathway has a dual effect on lung injury, and its specific mechanism and role need to be further investigated.</p></sec><sec disp-level="2" id="S005-S2002"><label>4.2</label><title>MAPK</title><p>The MAPK family, including extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38 MAPKs, participates in various physiological processes, including the regulation of lung function [<xref rid="CIT0073" ref-type="bibr">73</xref>]. The study has found that the use of the MNK (MAP Kinase-Interacting Kinase) inhibitor <ext-link ext-link-type="pmc:entrez-protein" xlink:href="CGP57380">CGP57380</ext-link> was able to prevent the infiltration of neutrophils in the alveoli, effectively reducing LPS-induced acute lung injury in mice [<xref rid="CIT0074" ref-type="bibr">74</xref>].</p><p>Exposure to cigaret smoke (CS) produces large amounts of reactive oxygen species (ROS). Continuous exposure to CS can lead to many chronic respiratory system diseases in the lungs. Huang et al. have discovered Eurotium cristatum (ECT) and Eurotium cristatum (ECP) reduce CS-induced oxidative stress and inflammation in mice through the MAPK pathway and induce CYP1A2 enzymes mRNA expression through PXR/AhR pathway to enhance liver metabolic detoxification ability and improve lung injury [<xref rid="CIT0075" ref-type="bibr">75</xref>]. In acute lung injury, as mentioned before, hyperoxia leads to more severe lung injury in male mice than female mice, accompanied by inhibited MAPK kinase pathway in male mice, while activated MAPK kinase pathway in female mice [<xref rid="CIT0076" ref-type="bibr">76</xref>]. However, the experiment did not provide direct evidence of CYP1A1 upregulation (data not shown) but mentioned that CYP1A1 may play a role in hyperoxic lung injury and its expression may be related to gender differences. This suggests that the gender-specific activation pattern of signaling pathways may be related to the expression and activity of CYP1A1, as CYP1A1 is an enzyme involved in metabolic and detoxification processes, and its activity may be regulated by the MAPK signaling pathway.</p><p>When mice were exposed to hyperoxia, the expression level of eIF4E protein, the key regulator of the MAPK signaling pathway, was found to be increased in WT mice and decreased in CYP1B1 enzyme null mice by reversed-phase protein array analysis [<xref rid="CIT0040" ref-type="bibr">40</xref>]. In summary, CYP1B1 enzyme and eIF4E may interact in hyperoxic lung injury, where the absence of CYP1B1 enzyme may regulate the cell's response to hyperoxia by affecting the expression of eIF4E, thereby influencing protein synthesis and cell proliferation. This interaction may have important implications for the development and treatment of hyperoxic lung injury.</p><p>These studies show that inhibition of the MAPK pathway and induction of CYP1A enzymes, as well as inhibition of CYP1B1 enzyme, helped to improve acute lung injury and inflammatory responses in mice under oxidative stress conditions.</p></sec><sec disp-level="2" id="S005-S2003"><label>4.3</label><title>NRF2</title><p>Nrf2 is a key transcription factor of the antioxidant response element (ARE) gene, which can regulate the synthesis and expression of antioxidant enzymes, participate in REDOX balance, energy metabolism, and maintain cell homeostasis [<xref rid="CIT0048" ref-type="bibr">48</xref>], with the protective role of Nrf2 in hyperoxygen-induced acute lung injury has been demonstrated [<xref rid="CIT0077" ref-type="bibr">77</xref>]. Notably, Callaway et al. reported that although the CYP1A inducer BNF significantly alleviates hyperoxia-induced pulmonary edema, it has no significant effect on hyperoxia-induced neutrophil infiltration and pulmonary inflammation in NRF2-deficient male mice, indicating that NRF2-independent pathways may also contribute to the anti-inflammatory effects of CYP1A during hyperoxia-induced lung injury [<xref rid="CIT0078" ref-type="bibr">78</xref>]. There is fine-tuned crosstalk between AhR and NRF2, the studies have shown that AhR interacts with Nrf2 positively or negatively [<xref rid="CIT0079" ref-type="bibr">79</xref>, <xref rid="CIT0080" ref-type="bibr">80</xref>]. AhR mediates the nuclear translocation of Nrf2, thereby activating the AhR-Nrf2-NQO1 signaling pathway and protecting cells from ROS-mediated oxidative damage [<xref rid="CIT0079" ref-type="bibr">79</xref>]. Weng et al. used siRNA to interfere with Nrf2 expression and found that Nrf2 siRNA significantly reduced the expression of Keap1 and NQO1 under hyperoxic conditions, and increased the susceptibility of A549 cells to hyperoxia-induced damage, as demonstrated by the aggravation of apoptosis. These findings suggest that Nrf2 plays a regulatory role in Keap1 and NQO1 [<xref rid="CIT0081" ref-type="bibr">81</xref>].</p><p>It has been found that NQO1 can regulate the expression of CYP1A1 enzymes. In the siRNA experiment containing NQO1-NQO1 promoter, high oxygen leads to decreased viability of BEAS-2B cells, and this effect is enhanced in cells treated with CYP1A1 enzyme SiRNA [<xref rid="CIT0082" ref-type="bibr">82</xref>]. The research results support the important roles of NQO1 and CYP1A1 in antioxidant defense and cellular protection, and suggest their potential synergistic effects in hyperoxia-induced lung injury.</p><p>Veith et al. have found that mice with similar expression levels of the NQO1 gene in WT and CYP1B1<sup>-/-</sup> showed similar levels of NRF2-dependent transcription [<xref rid="CIT0083" ref-type="bibr">83</xref>]. This may imply that, despite the absence of CYP1B1 affecting hyperoxia-induced lung injury, the NRF2 pathway's response to oxidative stress is relatively conserved in both genotypes. In addition, the presence of lipid peroxidation and oxidized DNA adducts was reduced in CYP1B1<sup>-/-</sup> mice [<xref rid="CIT0083" ref-type="bibr">83</xref>]. This suggests that CYP1B1 enzymes may indirectly regulate oxidative stress responses, such as DNA repair, through its metabolic activity, rather than directly increasing H<sub>2</sub>O<sub>2</sub> through reactive uncoupling, thereby indirectly promoting oxidation.</p></sec></sec><sec disp-level="1" id="S006"><label>5.</label><title>Regulation of CYP1 enzymes</title><sec disp-level="2" id="S006-S2001"><label>5.1</label><title>AHR-dependent regulation</title><p>The transcription of CYP1A1, CYP1A2, and CYP1B1 is regulated by the aromatic hydrocarbon receptor (AhR) [<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0084" ref-type="bibr">84</xref>]. AhR is a ligand-activated transcription factor distributed primarily in the cytoplasm and highly expressed in the human lung, thymus, kidney, and liver [<xref rid="CIT0015" ref-type="bibr">15</xref>]. The classical AhR pathway consists of four main steps: cytoplasmic complex formation, AhR transport to the nucleus, heterodimerization of AhR, and induction of CYP1 expression. CYP1 family members are responsible for various metabolic processes of exogenous and endogenous substrates.</p><p>In response to oxidative stress, various endogenous and exogenous ligands bind to the AhR, and then form the complexes that activate cytosolic AhR, and facilitate its translocation to the nucleus. In the nucleus, AhR forms dimers with AhR nuclear translocator protein, which then binds to xenobiotic responsive elements (XRE) and initiates the transcription of phase I enzymes such as CYP1 enzymes and phase II enzymes such as NAD(P)H: quinone oxidoreductase 1(NQO1) [<xref rid="CIT0083" ref-type="bibr">83</xref>, <xref rid="CIT0085" ref-type="bibr">85</xref>]. Exposure to high levels of oxygen has been shown to activate the AhR and induce the expression of CYP1A1 and NQO1 enzymes in fetal human pulmonary microvascular endothelial cells (HPMEC) [<xref rid="CIT0062" ref-type="bibr">62</xref>]. Notably, hyperoxia-induced CYP1A1 and NQO1 expression were significantly decreased in AhR-deficient cells [<xref rid="CIT0062" ref-type="bibr">62</xref>] (<xref rid="F0004" ref-type="fig">Figure 4</xref>).
<fig position="float" id="F0004" orientation="portrait"><label>Figure 4.</label><caption><p>Mechanism of AhR regulating CYP1 enzymes. Exogenous ligands such as TCDD(2,3,7,8-tetrachlorodibenzo-p-dioxin), PAHs (polycyclic aromatic hydrocarbons), or endogenous ligands such as FIZC (6-formylindolo[3,2-b]carbazole) bind to AHR and transport to the nucleus. It forms complexes with ARNT in the nucleus and binds to xenobiotic reaction elements (XREs) to regulate gene expression of the CYP1 family, including CYP1A1, CYP1A2, and CYP1B1 enzymes. It also regulates the expression</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="YRER_A_2550807_F0004_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="YRER_A_2550807_F0004_PB.jpg"/></alternatives></fig></p></sec><sec disp-level="2" id="S006-S2002"><label>5.2</label><title>Medicinal drugs</title><p>Many drugs can regulate the expression of CYP1 enzymes. For instance, omeprazole, a proton pump inhibitor used to treat acid-related diseases, not only serves its primary function but also plays a role in enzyme regulation; it activates AhR and induces CYP1A enzymes, which helps to alleviate hyperoxia-induced toxicity in H441 cells [<xref rid="CIT0064" ref-type="bibr">64</xref>]. Consistent with this, Shivanna et al. have discovered that omeprazole increases the expression of CYP1A1 mRNA and protein in mouse lungs in a dose-dependent manner [<xref rid="CIT0086" ref-type="bibr">86</xref>]. Similarly, Nishimura et al. have found that in human hepatocytes, omeprazole increases the expression of CYP1A1, CYP1A2, and CYP1B1 mRNA [<xref rid="CIT0087" ref-type="bibr">87</xref>]. Furthermore, Posti et al. have observed in primary mouse hepatocytes that phenobarbital (PB) induces the activity of CYP1A1 and CYP1A2 enzymes [<xref rid="CIT0088" ref-type="bibr">88</xref>]. In addition to these findings, Patel reported that leflunomide induces the expression of CYP1A1 and CYP1A2 enzymes in the lungs through an AhR-mediated mechanism [<xref rid="CIT0089" ref-type="bibr">89</xref>]. Taken together, these studies highlight the ability of various drugs to modulate the expression and activity of CYP1 enzymes, which may have significant implications for drug metabolism and toxicity.</p><p>In addition to drugs that can induce the expression of CYP1 enzymes, some medications in clinical use can inhibit the expression of CYP1A enzymes. Common inhibitors of CYP1A1 enzyme include norfluoxetine [<xref rid="CIT0090" ref-type="bibr">90</xref>], sertraline [<xref rid="CIT0090" ref-type="bibr">90</xref>], fluvoxamine [<xref rid="CIT0090" ref-type="bibr">90</xref>], and ketoconazole [<xref rid="CIT0091" ref-type="bibr">91</xref>]. Additionally, some therapeutic drugs, including grepafloxacin, carbamazepine, dihydrobenzothiazepine, furfural, isoniazid, rofecoxib, chlorpromazine, thiopronine, and zileuton, are inhibitors of CYP1A2 enzyme [<xref rid="CIT0090" ref-type="bibr">90</xref>]. Some commonly used anticancer drugs in clinical practice are competitive inhibitors of the CYP1B1 enzyme, such as flutamide, paclitaxel, mitoxantrone, and docetaxel [<xref rid="CIT0026" ref-type="bibr">26</xref>] (<xref rid="T0001" ref-type="table">Table 1</xref>).
<table-wrap position="float" id="T0001" orientation="portrait"><label>Table 1.</label><caption><p>Medicine drugs.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="1" rowspan="1">CYP enzyme</th><th align="center" colspan="1" rowspan="1">Inducers</th><th align="center" colspan="1" rowspan="1">Inhibitors</th><th align="center" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">CYP1A1</td><td align="left" colspan="1" rowspan="1">Omeprazole, Phenobarbital, Leflunomide</td><td align="left" colspan="1" rowspan="1">Norfluoxetine, Sertraline, Fluvoxamine, Ketoconazole</td><td align="left" colspan="1" rowspan="1">[<xref rid="CIT0086" ref-type="bibr">86&#8211;91</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP1A2</td><td align="left" colspan="1" rowspan="1">Omeprazole, Phenobarbital, Leflunomide</td><td align="left" colspan="1" rowspan="1">Grepafloxacin, Carbamazepine, Dihydrobenzothiazepine, Furfural, Isoniazid, Rofecoxib, Chlorpromazine, Thiopronine, Zileuton</td><td align="left" colspan="1" rowspan="1">[<xref rid="CIT0087" ref-type="bibr">87</xref>,<xref rid="CIT0089" ref-type="bibr">89</xref>,<xref rid="CIT0090" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP1B1</td><td align="left" colspan="1" rowspan="1">Omeprazole</td><td align="left" colspan="1" rowspan="1">Flutamide, Paclitaxel, Mitoxantrone, Docetaxel</td><td align="left" colspan="1" rowspan="1">[<xref rid="CIT0087" ref-type="bibr">87</xref>,<xref rid="CIT0026" ref-type="bibr">26</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec disp-level="2" id="S006-S2003"><label>5.3</label><title>Environmental pollutants</title><p>The expression of the CYP1 enzyme system can be induced and regulated by a variety of compounds, including some environmental pollutants (<xref rid="T0002" ref-type="table">Table 2</xref>). These compounds typically bind to AhR, activating the downstream expression of CYP1A genes, thereby affecting the activity of the cytochrome P450 enzyme system.
<table-wrap position="float" id="T0002" orientation="portrait"><label>Table 2.</label><caption><p>Environmental pollutants.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="1" rowspan="1">CYP enzyme</th><th align="center" colspan="1" rowspan="1">Inducers</th><th align="center" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">CYP1A1</td><td align="left" colspan="1" rowspan="1">TCDD, PAHs, BaP,</td><td align="left" colspan="1" rowspan="1">[<xref rid="CIT0092" ref-type="bibr">92</xref>,<xref rid="CIT0044" ref-type="bibr">44</xref>,<xref rid="CIT0094" ref-type="bibr">94</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP1A2</td><td align="left" colspan="1" rowspan="1">TCDD, PAHs</td><td align="left" colspan="1" rowspan="1">[<xref rid="CIT0092" ref-type="bibr">92</xref>,<xref rid="CIT0044" ref-type="bibr">44</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP1B1</td><td align="left" colspan="1" rowspan="1">TCDD, PAHs, BaP</td><td align="left" colspan="1" rowspan="1">[<xref rid="CIT0093" ref-type="bibr">93</xref>,<xref rid="CIT0044" ref-type="bibr">44</xref>,<xref rid="CIT0094" ref-type="bibr">94</xref>]</td></tr></tbody></table></table-wrap></p><p>For example, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is one of the most toxic compounds known. As a planar polychlorinated dibenzo-p-dioxin, it has a strong binding affinity for the AhR and is an effective inducer of CYP1. A study has found that CYP1A1 enzyme and CYP1A2 enzyme are highly induced by TCDD in numerous tissues, including the liver, lungs, kidneys, and small intestine [<xref rid="CIT0092" ref-type="bibr">92</xref>]. In another study, Aude Jacob et al. have found that TCDD induces the expression of CYP1B1 enzyme in the microvasculature of the rat brain through the AhR [<xref rid="CIT0093" ref-type="bibr">93</xref>]. In addition to TCDD, polycyclic aromatic hydrocarbons (PAHs) are also an important class of CYP1 enzyme inducers, which mainly originate from the incomplete combustion of organic matter and possess bioaccumulative properties and multiple toxicities. Rachel Stading et al. have found that PAH exposure may regulate hyperoxic lung injury by inducing the expression of CYP1 enzymes, newborn mice exposed to PAH in utero are more susceptible to hyperoxic lung injury than those not exposed to PAH [<xref rid="CIT0044" ref-type="bibr">44</xref>]. Additionally, the environmental carcinogen benzo [a]pyrene (BaP) is a representative compound of polycyclic aromatic hydrocarbons. John et al. have discovered in the normal human mammary epithelial cell (NHMEC) that BaP significantly induced the expression of CYP1A1 enzyme and CYP1B1 enzyme [<xref rid="CIT0094" ref-type="bibr">94</xref>].</p></sec><sec disp-level="2" id="S006-S2004"><label>5.4</label><title>Flavonoids</title><p>In addition to environmental pollutants, some flavonoids can also regulate the expression of CYP1 enzymes, including quercetin (QU), BNF, alpha-naphthoflavone (ANF), isorhamnetin, and kaempferol. Among them, quercetin is one of the most common flavonoids, found in various fruits, vegetables, and beverages. Maturu et al. found that newborn mice treated with quercetin could prevent hyperoxic lung injury by enhancing the expression of CYP1 enzymes [<xref rid="CIT0033" ref-type="bibr">33</xref>]. Furthermore, BNF can also induce the expression of CYP1A enzymes, in vivo microarray analysis has shown mice treated with BNF act on AhR, and then induce CYP1A1 gene expression in the lung under high oxygen conditions [<xref rid="CIT0008" ref-type="bibr">8</xref>]. A study has found that after pretreatment with BNF, the activity of CYP1A1 and CYP1A2 in the lungs and liver of mice significantly increased [<xref rid="CIT0078" ref-type="bibr">78</xref>]. Another experiment discovered that BNF can pass through the placenta, and when pregnant mice were treated with BNF, it led to a significant increase in the activity of CYP1</p><p>A1 and CYP1A2 enzymes in the liver and lungs of newborn pups when they were exposed to a hyperoxic environment after birth [<xref rid="CIT0095" ref-type="bibr">95</xref>]. Contrary to the effects of BNF, ANF acts as an inhibitor of CYP1 enzymes and can reduce their activity [<xref rid="CIT0096" ref-type="bibr">96</xref>]. In the human bronchial epithelial cell line BEAS-2B, ANF significantly reduced the expression of CYP1A1 enzyme and CYP1B1 enzyme enhanced by TCDD [<xref rid="CIT0078" ref-type="bibr">78</xref>]. In addition to ANF, N-(3,5-dichlorophenyl)cyclopropanecarboxamide (DCPCC) is also a novel CYP1 enzymes inhibitor that shows high selectivity and inhibitory effect on CYP1A2 enzyme [<xref rid="CIT0096" ref-type="bibr">96</xref>]. Additionally, other studies have found that the flavonoids isorhamnetin and kaempferol can also inhibit the expression of CYP1 enzymes [<xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0097" ref-type="bibr">97</xref>] (<xref rid="T0003" ref-type="table">Table 3</xref>).
<table-wrap position="float" id="T0003" orientation="portrait"><label>Table 3.</label><caption><p>Flavonoids.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="1" rowspan="1">CYP enzyme</th><th align="center" colspan="1" rowspan="1">Inducers</th><th align="center" colspan="1" rowspan="1">Inhibitors</th><th align="center" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">CYP1A1</td><td align="left" colspan="1" rowspan="1">QU, BNF</td><td align="left" colspan="1" rowspan="1">ANF, flavonoids isorhamnetin, kaempferol</td><td align="left" colspan="1" rowspan="1">[<xref rid="CIT0008" ref-type="bibr">8</xref>,<xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0033" ref-type="bibr">33</xref>,<xref rid="CIT0078" ref-type="bibr">78</xref>,<xref rid="CIT0095" ref-type="bibr">95</xref>,<xref rid="CIT0097" ref-type="bibr">97</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP1A2</td><td align="left" colspan="1" rowspan="1">QU, BNF</td><td align="left" colspan="1" rowspan="1">DCPCC, flavonoids isorhamnetin, kaempferol</td><td align="left" colspan="1" rowspan="1">[<xref rid="CIT0008" ref-type="bibr">8</xref>,<xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0033" ref-type="bibr">33</xref>,<xref rid="CIT0078" ref-type="bibr">78</xref>,<xref rid="CIT0095" ref-type="bibr">95</xref>,<xref rid="CIT0097" ref-type="bibr">97</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP1B1</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">ANF, flavonoids isorhamnetin, kaempferol</td><td align="left" colspan="1" rowspan="1">[<xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0096" ref-type="bibr">96</xref>,<xref rid="CIT0097" ref-type="bibr">97</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec disp-level="2" id="S006-S2005"><label>5.5</label><title>Exercrise</title><p>Studies have shown that exercise can actively regulate the innate and adaptive immune responses in the lungs in respiratory system diseases, such as asthma [<xref rid="CIT0098" ref-type="bibr">98</xref>], pulmonary fibrosis [<xref rid="CIT0099" ref-type="bibr">99</xref>], and chronic obstructive pulmonary Disease (COPD) [<xref rid="CIT0100" ref-type="bibr">100</xref>]. Additionally, exercise has been shown to improve phase I drug metabolism in the kidneys without affecting phase II processes, and regular exercise can increase the concentration and activity of some enzymes in the kidneys [<xref rid="CIT0101" ref-type="bibr">101</xref>]. Lee et al. have discovered that in an aged rat model, regular swimming exercise can increase the expression of hepatic CYP1A enzymes. Compared to the control group, CYP1A2 mRNA expression increased in the livers of rats in both the short-term and long-term exercise groups, and CYP1A protein levels were significantly upregulated in the livers of the long-term exercise group [<xref rid="CIT0102" ref-type="bibr">102</xref>]. In another study, Knudsen et al. have found an increase in CYP1A protein expression in the liver tissue of mice after 16 weeks of combined voluntary wheel running and treadmill exercise. In addition, in a clinical study of 23 healthy men, 30 days of vigorous exercise led to a 70% increase in the CYP1A2 ratio [<xref rid="CIT0103" ref-type="bibr">103</xref>]. Similarly, Frenkl et al. have found that intense exercise led to a significant increase in serum GH concentration in young ice hockey players, which in turn resulted in an increased Ct value for CYP1A2 enzyme [<xref rid="CIT0104" ref-type="bibr">104</xref>]. In summary, long-term or high-intensity exercise can increase the expression levels of CYP1A1 enzyme and CYP1A2 enzyme in different tissues. The above studies suggest that the regulatory effect of exercise on CYP1 enzymes is influenced by a variety of factors, including exercise intensity and duration of exercise, individual physiological status, and environmental factors.</p></sec></sec><sec disp-level="1" id="S007"><label>6.</label><title>Clinical implications</title><p>Previous animal studies have shown that in hyperoxic lung injury, the upregulation of CYP1A1 and CYP1A2 enzymes can promote the metabolism of lipid hydroperoxides and quinone substances, such as F2-isoprostanes and isofurans, thereby alleviating oxidative stress [<xref rid="CIT0105" ref-type="bibr">105</xref>]. However, there is currently a lack of research exploring the clinical application of targeting CYP1 enzymes, which is a key area for future work.</p><p>Members of the CYP1 family are involved in drug metabolism, affecting the biotransformation of drugs. Clarifying the correlation between CYP1 family members and drugs, and exploring the development of drugs that selectively enhance CYP1A enzymes expression and inhibit CYP1B1 enzyme, will contribute to the formulation of treatment strategies for acute lung injury induced by oxidative stress. On the one hand, drugs targeting CYP1 enzyme metabolic reactions may be a potential direction for the treatment of acute lung injury. On the other hand, inducers and inhibitors related to CYP1 family members may also be potential therapeutic targets. In the clinical setting, pregnant women at risk of preterm birth often take corticosteroids before birth to reduce the risk of their newborns developing BPD (Bronchopulmonary Dysplasia) [<xref rid="CIT0106" ref-type="bibr">106</xref>]. Similarly, treatment of pregnant women at risk of preterm birth with BNF or other flavonoids may lead to better preparation of newborns to cope with hyperoxic exposure due to the induction of CYP1A enzymes through the placenta [<xref rid="CIT0095" ref-type="bibr">95</xref>]. Additionally, the expression of CYP1A2 declines with age, and long-term regular exercise can delay the age-related decline in some CYPs, thereby improving drug clearance levels [<xref rid="CIT0102" ref-type="bibr">102</xref>].</p><p>In summary, understanding the inducers and inhibitors of CYP1 enzymes and developing methods to selectively regulate the expression of CYP1 enzymes can help establish treatment strategies for acute lung injury and provide a theoretical basis for the pathogenesis and clinical prevention and treatment of acute lung injury.</p><p>Future research directions should focus on: 1) Elucidating the underlying mechanisms; 2) Designing and developing novel delivery systems, such as nanoparticles, liposomes, or inhalable formulations, for CYP1-specific modulators to enhance pulmonary drug concentration, reduce systemic exposure and side effects, and evaluate their intrapulmonary distribution, pharmacodynamics, and preliminary safety; 3) Discovering and optimizing specific modulators. 4) Establishing clinical-grade assays for real-time CYP1 enzyme activity monitoring. These innovative approaches may overcome current limitations in CYP-based therapeutic development.</p></sec><sec disp-level="1" id="S008"><label>7.</label><title>Conclusion</title><p>This paper has reviewed that the CYP1 enzyme family, comprising CYP1A1, CYP1A2, and CYP1B1, exhibits contrasting biological roles in various forms of acute lung injury, including hyperoxia-induced lung injury, LPS- or CLP-associated lung injury, and COVID-19. The activity of these enzymes is tightly regulated by the AhR.</p><p>CYP1A enzymes confer significant protection against lung injury in hyperoxic conditions, sepsis, and COVID-19 pneumonia. Their protective mechanisms involve metabolizing lipid peroxides, enhancing antioxidant capacity through upregulation of NRF2 and activation of NQO1, and suppressing inflammatory responses via modulation of NF-&#954;B signaling. It is noteworthy that NF-&#954;B exerts complex, context-dependent effects in inflammation, displaying dual regulatory properties dictated by its specific subunit composition and cellular microenvironment. Pharmacological induction of CYP1A expression using AhR agonists such as BNF, quercetin, and omeprazole represents a promising clinical intervention strategy.</p><p>In contrast, CYP1B1 exacerbates tissue damage in hyperoxic lung injury by activating pro-inflammatory signaling pathways, and metabolizing environmental toxins including polycyclic aromatic hydrocarbons. During sepsis-related lung injury, CYP1B1 may impair functions of basal cells, macrophages, and interstitial cells [<xref rid="CIT0049" ref-type="bibr">49</xref>]. Nevertheless, the precise mechanistic role of CYP1B1 in ALI pathogenesis remains incompletely defined, particularly regarding its cell-type-specific regulatory functions and interactions with signaling cascades, necessitating further investigation.</p><p>These findings possess substantial translational significance. The development of selective CYP1A inducers, exemplified by flavonoids, or CYP1B1 inhibitors such as 2,4,3&#8217;,5'-Tetramethoxystilbene (TMS), constitutes a novel therapeutic approach for ALI. Furthermore, cross-organ protective strategies involving physical exercise, pharmacological agents such as omeprazole, and placenta-targeted delivery of AhR agonists show potential for ameliorating lung injury through modulation of CYP1 enzyme activities. Future research priorities include elucidating the complex interplay between CYP1 enzymes and key signaling pathways (AhR/NRF2/NF-&#954;B/MAPK), developing dual-targeting modulators, and establishing clinical methods for real-time monitoring of CYP1 activity to facilitate personalized therapeutic approaches. Collectively, differential targeting of CYP1 enzymes represents an innovative strategy for ALI intervention. Continued mechanistic research and clinical translation in this domain will advance precision medicine for respiratory diseases.</p></sec></body><back><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zanger</surname><given-names>UM</given-names></string-name>, <string-name name-style="western"><surname>Schwab</surname><given-names>M.</given-names></string-name></person-group><article-title>Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation</article-title>. <source>Pharmacol Ther</source>. <year>2013</year>;<volume>138</volume>(<issue>1</issue>):<fpage>103</fpage>&#8211;<lpage>141</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.12.007</pub-id><pub-id pub-id-type="pmid">23333322</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kwon</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chun</surname><given-names>YJ.</given-names></string-name></person-group><article-title>Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes</article-title>. <source>Arch Pharm Res</source>. <year>2021</year>;<volume>44</volume>(<issue>1</issue>):<fpage>63</fpage>&#8211;<lpage>83</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12272-021-01306-w</pub-id><pub-id pub-id-type="pmid">33484438</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elfaki</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Mir</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Almutairi</surname><given-names>FM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cytochrome P450: polymorphisms and roles in cancer, diabetes and atherosclerosis</article-title>. <source>Asian Pac J Cancer Prev</source>. <year>2018</year>;<volume>19</volume>(<issue>8</issue>):<fpage>2057</fpage>&#8211;<lpage>2070</lpage>.<pub-id pub-id-type="pmid">30139042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22034/APJCP.2018.19.8.2057</pub-id><pub-id pub-id-type="pmcid">PMC6171375</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lingappan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Sex-specific differences in hyperoxic lung injury in mice: role of cytochrome P450 (CYP)1A</article-title>. <source>Toxicology</source>. <year>2015</year>;<volume>331</volume>:<fpage>14</fpage>&#8211;<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tox.2015.01.019</pub-id><pub-id pub-id-type="pmid">25703676</pub-id><pub-id pub-id-type="pmcid">PMC4406849</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Go</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>KC.</given-names></string-name></person-group><article-title>Cytochrome P450 1 family and cancers</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2015</year>;<volume>147</volume>:<fpage>24</fpage>&#8211;<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsbmb.2014.11.003</pub-id><pub-id pub-id-type="pmid">25448748</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mescher</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Haarmann-Stemmann</surname><given-names>T.</given-names></string-name></person-group><article-title>Modulation of CYP1A1 metabolism: from adverse health effects to chemoprevention and therapeutic options</article-title>. <source>Pharmacol Ther</source>. <year>2018</year>;<volume>187</volume>:<fpage>71</fpage>&#8211;<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pharmthera.2018.02.012</pub-id><pub-id pub-id-type="pmid">29458109</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Badawy</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Metabolism and mechanism of human cytochrome P450 enzyme 1A2</article-title>. <source>Curr Drug Metab</source>. <year>2021</year>;<volume>22</volume>(<issue>1</issue>):<fpage>40</fpage>&#8211;<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.2174/18755453MTEyCOTgcx</pub-id><pub-id pub-id-type="pmid">33397254</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maturu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wei-Liang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Newborn mice lacking the gene for Cyp1a1 Are more susceptible to oxygen-mediated lung injury, and Are rescued by postnatal beta-naphthoflavone administration: implications for bronchopulmonary dysplasia in premature infants</article-title>. <source>Toxicol Sci</source>. <year>2017</year>;<volume>157</volume>(<issue>1</issue>):<fpage>260</fpage>&#8211;<lpage>271</lpage>. doi:<pub-id pub-id-type="doi">10.1093/toxsci/kfx036</pub-id><pub-id pub-id-type="pmid">28201809</pub-id><pub-id pub-id-type="pmcid">PMC5837454</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nebert</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Dalton</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Okey</surname><given-names>AB</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>(<issue>23</issue>):<fpage>23847</fpage>&#8211;<lpage>23850</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.R400004200</pub-id><pub-id pub-id-type="pmid">15028720</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dutour</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Poirier</surname><given-names>D.</given-names></string-name></person-group><article-title>Inhibitors of cytochrome P450 (CYP) 1B1</article-title>. <source>Eur J Med Chem</source>. <year>2017</year>;<volume>135</volume>:<fpage>296</fpage>&#8211;<lpage>306</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejmech.2017.04.042</pub-id><pub-id pub-id-type="pmid">28458135</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Srejber</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Navratilova</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Paloncyova</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Membrane-attached mammalian cytochromes P450: An overview of the membrane's effects on structure, drug binding, and interactions with redox partners</article-title>. <source>J Inorg Biochem</source>. <year>2018</year>;<volume>183</volume>:<fpage>117</fpage>&#8211;<lpage>136</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jinorgbio.2018.03.002</pub-id><pub-id pub-id-type="pmid">29653695</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>H</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The AKR1C1-CYP1B1-cAMP signaling axis controls tumorigenicity and ferroptosis susceptibility of extrahepatic cholangiocarcinoma</article-title>. <source>Cell Death Differ</source>. <year>2025</year>;<volume>32</volume>(<issue>3</issue>):<fpage>506</fpage>&#8211;<lpage>520</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41418-024-01407-1</pub-id><pub-id pub-id-type="pmid">39478199</pub-id><pub-id pub-id-type="pmcid">PMC11894074</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xie</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Colistin induces oxidative stress and apoptotic cell death through the activation of the AhR/CYP1A1 pathway in PC12 cells</article-title>. <source>Antioxidants (Basel)</source>. <year>2024</year>;<volume>13</volume>(<issue>7</issue>):<fpage>827</fpage>. doi:<pub-id pub-id-type="doi">10.3390/antiox13070827</pub-id><pub-id pub-id-type="pmid">39061896</pub-id><pub-id pub-id-type="pmcid">PMC11273690</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haron</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Dale</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Evaluation of the herb-drug interaction potential of commonly used botanicals on the US market with regard to PXR- and AhR-mediated influences on CYP3A4 and CYP1A2</article-title>. <source>J Diet Suppl</source>. <year>2023</year>;<volume>20</volume>(<issue>5</issue>):<fpage>763</fpage>&#8211;<lpage>776</lpage>. doi:<pub-id pub-id-type="doi">10.1080/19390211.2022.2110351</pub-id><pub-id pub-id-type="pmid">36017806</pub-id><pub-id pub-id-type="pmcid">PMC12083740</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seok</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Structural hierarchy controlling dimerization and target DNA recognition in the AHR transcriptional complex</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2017</year>;<volume>114</volume>(<issue>21</issue>):<fpage>5431</fpage>&#8211;<lpage>5436</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1617035114</pub-id><pub-id pub-id-type="pmid">28396409</pub-id><pub-id pub-id-type="pmcid">PMC5448172</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bae</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rhee</surname><given-names>SG</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Regulation of reactive oxygen species generation in cell signaling</article-title>. <source>Mol Cells</source>. <year>2011</year>;<volume>32</volume>(<issue>6</issue>):<fpage>491</fpage>&#8211;<lpage>509</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10059-011-0276-3</pub-id><pub-id pub-id-type="pmid">22207195</pub-id><pub-id pub-id-type="pmcid">PMC3887685</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></string-name></person-group><article-title>Effects of xenobiotics on CYP1 enzyme-mediated biotransformation and bioactivation of estradiol</article-title>. <source>Drug Metab Rev</source>. <year>2023</year>;<volume>55</volume>(<issue>1-2</issue>):<fpage>1</fpage>&#8211;<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1080/03602532.2023.2177671</pub-id><pub-id pub-id-type="pmid">36823774</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Choudhary</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Jansson</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Stoilov</surname><given-names>I</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1</article-title>. <source>Drug Metab Dispos</source>. <year>2004</year>;<volume>32</volume>(<issue>8</issue>):<fpage>840</fpage>&#8211;<lpage>847</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.32.8.840</pub-id><pub-id pub-id-type="pmid">15258110</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chang</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>G</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin</article-title>. <source>J Pineal Res</source>. <year>2010</year>;<volume>48</volume>(<issue>1</issue>):<fpage>55</fpage>&#8211;<lpage>64</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1600-079X.2009.00724.x</pub-id><pub-id pub-id-type="pmid">19919601</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Sha</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Association of human cytochrome P450 1A1 (CYP1A1) and sulfotransferase 1A1 (SULT1A1) polymorphisms with differential metabolism and cytotoxicity of aminoflavone</article-title>. <source>Mol Cancer Ther</source>. <year>2010</year>;<volume>9</volume>(<issue>10</issue>):<fpage>2803</fpage>&#8211;<lpage>2813</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-10-0597</pub-id><pub-id pub-id-type="pmid">20713530</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lewis</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Korprasertthaworn</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Miners</surname><given-names>JO.</given-names></string-name></person-group><article-title>Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy</article-title>. <source>Pharmacogenet Genomics</source>. <year>2016</year>;<volume>26</volume>(<issue>10</issue>):<fpage>453</fpage>&#8211;<lpage>461</lpage>. doi:<pub-id pub-id-type="doi">10.1097/FPC.0000000000000236</pub-id><pub-id pub-id-type="pmid">27428168</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patterson</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>GI.</given-names></string-name></person-group><article-title>Tumour cytochrome P450 and drug activation</article-title>. <source>Curr Pharm Des</source>. <year>2002</year>;<volume>8</volume>(<issue>15</issue>):<fpage>1335</fpage>&#8211;<lpage>1347</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1381612023394502</pub-id><pub-id pub-id-type="pmid">12052211</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bart</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Morais</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Vangala</surname><given-names>VR</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cytochrome P450 binding and bioactivation of tumor-targeted duocarmycin agents</article-title>. <source>Drug Metab Dispos</source>. <year>2022</year>;<volume>50</volume>(<issue>1</issue>):<fpage>49</fpage>&#8211;<lpage>57</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.121.000642</pub-id><pub-id pub-id-type="pmid">34607808</pub-id><pub-id pub-id-type="pmcid">PMC8969195</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raju</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Narendra</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname><given-names>H</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Scaffold hopping for designing of potent and selective CYP1B1 inhibitors to overcome docetaxel resistance: synthesis and evaluation</article-title>. <source>J Biomol Struct Dyn</source>. <year>2024</year>: <fpage>1</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2024.2310770</pub-id><pub-id pub-id-type="pmid">38356135</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>A.G. R, J.B. S, K.G. A, D.D. K</collab></person-group>. <article-title>Effect of cyp1a1, cyp1b1 and cyp2c gene polymorphisms on doxorubicin and paclitaxel</article-title>. <source>Bioinformation</source>. <year>2024</year>;<volume>20</volume>(<issue>10</issue>):<fpage>1244</fpage>&#8211;<lpage>1250</lpage>. doi:<pub-id pub-id-type="doi">10.6026/9732063002001244</pub-id><pub-id pub-id-type="pmid">40092865</pub-id><pub-id pub-id-type="pmcid">PMC11904140</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rochat</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Morsman</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>GI</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?</article-title><source>J Pharmacol Exp Ther</source>. <year>2001</year>;<volume>296</volume>(<issue>2</issue>):<fpage>537</fpage>&#8211;<lpage>541</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0022-3565(24)38762-2</pub-id><pub-id pub-id-type="pmid">11160641</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khafagy</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>El-Guendy</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tantawy</surname><given-names>MA</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Novel CYP1B1 mutations and a possible prognostic use for surgical management of congenital glaucoma</article-title>. <source>Int J Ophthalmol</source>. <year>2019</year>;<volume>12</volume>(<issue>4</issue>):<fpage>607</fpage>&#8211;<lpage>614</lpage>.<pub-id pub-id-type="pmid">31024815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18240/ijo.2019.04.14</pub-id><pub-id pub-id-type="pmcid">PMC6469545</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Williams-Brown</surname><given-names>MY</given-names></string-name>, <string-name name-style="western"><surname>Salih</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2011</year>;<volume>126</volume>(<issue>3-5</issue>):<fpage>78</fpage>&#8211;<lpage>86</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsbmb.2011.05.001</pub-id><pub-id pub-id-type="pmid">21600284</pub-id><pub-id pub-id-type="pmcid">PMC3421458</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maayah</surname><given-names>ZH</given-names></string-name>, <string-name name-style="western"><surname>Althurwi</surname><given-names>HN</given-names></string-name>, <string-name name-style="western"><surname>Abdelhamid</surname><given-names>G</given-names></string-name>, <etal>et al.</etal></person-group><article-title>CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism</article-title>. <source>Pharmacol Res</source>. <year>2016</year>;<volume>105</volume>:<fpage>28</fpage>&#8211;<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.phrs.2015.12.016</pub-id><pub-id pub-id-type="pmid">26772815</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fan</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Brodie</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Slutsky</surname><given-names>AS.</given-names></string-name></person-group><article-title>Acute respiratory distress syndrome: advances in diagnosis and treatment</article-title>. <source>JAMA</source>. <year>2018</year>;<volume>319</volume>(<issue>7</issue>):<fpage>698</fpage>&#8211;<lpage>710</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2017.21907</pub-id><pub-id pub-id-type="pmid">29466596</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moorthy</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Parker</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>CV</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Potentiation of oxygen-induced lung injury in rats by the mechanism-based cytochrome P-450 inhibitor, 1-aminobenzotriazole</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2000</year>;<volume>292</volume>(<issue>2</issue>):<fpage>553</fpage>&#8211;<lpage>560</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0022-3565(24)35325-X</pub-id><pub-id pub-id-type="pmid">10640292</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lingappan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Maturu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>YW</given-names></string-name>, <etal>et al.</etal></person-group><article-title>beta-Naphthoflavone treatment attenuates neonatal hyperoxic lung injury in wild type and Cyp1a2-knockout mice</article-title>. <source>Toxicol Appl Pharmacol</source>. <year>2018</year>;<volume>339</volume>:<fpage>133</fpage>&#8211;<lpage>142</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.taap.2017.11.017</pub-id><pub-id pub-id-type="pmid">29180065</pub-id><pub-id pub-id-type="pmcid">PMC5758404</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maturu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wei-Liang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Androutsopoulos</surname><given-names>VP</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Quercetin attenuates the hyperoxic lung injury in neonatal mice: implications for bronchopulmonary dysplasia (BPD)</article-title>. <source>Food Chem Toxicol</source>. <year>2018</year>;<volume>114</volume>:<fpage>23</fpage>&#8211;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.fct.2018.02.026</pub-id><pub-id pub-id-type="pmid">29432836</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shivanna</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Omeprazole attenuates hyperoxic lung injury in mice via aryl hydrocarbon receptor activation and is associated with increased expression of cytochrome P4501A enzymes</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2011</year>;<volume>339</volume>(<issue>1</issue>):<fpage>106</fpage>&#8211;<lpage>114</lpage>. doi:<pub-id pub-id-type="doi">10.1124/jpet.111.182980</pub-id><pub-id pub-id-type="pmid">21768223</pub-id><pub-id pub-id-type="pmcid">PMC3186283</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Maturu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>YW</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Hyperoxia-mediated transcriptional activation of cytochrome P4501A1 (CYP1A1) and decreased susceptibility to oxygen-mediated lung injury in newborn mice</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2018</year>;<volume>495</volume>(<issue>1</issue>):<fpage>408</fpage>&#8211;<lpage>413</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2017.10.166</pub-id><pub-id pub-id-type="pmid">29101037</pub-id><pub-id pub-id-type="pmcid">PMC5743196</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Couroucli</surname><given-names>XI</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Augmented oxygen-mediated transcriptional activation of cytochrome P450 (CYP)1A expression and increased susceptibilities to hyperoxic lung injury in transgenic mice carrying the human CYP1A1 or mouse 1A2 promoter in vivo</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2011</year>;<volume>407</volume>(<issue>1</issue>):<fpage>79</fpage>&#8211;<lpage>85</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2011.02.113</pub-id><pub-id pub-id-type="pmid">21362406</pub-id><pub-id pub-id-type="pmcid">PMC3123253</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dinu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Veith</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Mechanistic role of cytochrome P450 (CYP)1B1 in oxygen-mediated toxicity in pulmonary cells: A novel target for prevention of hyperoxic lung injury</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2016</year>;<volume>476</volume>(<issue>4</issue>):<fpage>346</fpage>&#8211;<lpage>351</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2016.05.125</pub-id><pub-id pub-id-type="pmid">27235555</pub-id><pub-id pub-id-type="pmcid">PMC4935552</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smerdova</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Neca</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Svobodova</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Inflammatory mediators accelerate metabolism of benzo[a]pyrene in rat alveolar type II cells: the role of enhanced cytochrome P450 1B1 expression</article-title>. <source>Toxicology</source>. <year>2013</year>;<volume>314</volume>(<issue>1</issue>):<fpage>30</fpage>&#8211;<lpage>38</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tox.2013.09.001</pub-id><pub-id pub-id-type="pmid">24025706</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thakur</surname><given-names>VS</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>YW</given-names></string-name>, <string-name name-style="western"><surname>Lingappan</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Increased susceptibility to hyperoxic lung injury and alveolar simplification in newborn rats by prenatal administration of benzo[a]pyrene</article-title>. <source>Toxicol Lett</source>. <year>2014</year>;<volume>230</volume>(<issue>2</issue>):<fpage>322</fpage>&#8211;<lpage>332</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.toxlet.2014.03.006</pub-id><pub-id pub-id-type="pmid">24657529</pub-id><pub-id pub-id-type="pmcid">PMC4169345</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grimm</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Stading</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>MJ</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Loss of cytochrome P450 (CYP)1B1 mitigates hyperoxia response in adult mouse lung by reprogramming metabolism and translation</article-title>. <source>Redox Biol</source>. <year>2023</year>;<volume>64</volume>:<fpage>102790</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.redox.2023.102790</pub-id><pub-id pub-id-type="pmid">37348155</pub-id><pub-id pub-id-type="pmcid">PMC10271936</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tian</surname><given-names>LX</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Knockout of cytochrome P450 1A1 enhances lipopolysaccharide-induced acute lung injury in mice by targeting NF-kappaB activation</article-title>. <source>FEBS Open Bio</source>. <year>2020</year>;<volume>10</volume>(<issue>11</issue>):<fpage>2316</fpage>&#8211;<lpage>2328</lpage>. doi:<pub-id pub-id-type="doi">10.1002/2211-5463.12977</pub-id><pub-id pub-id-type="pmcid">PMC7609787</pub-id><pub-id pub-id-type="pmid">32935470</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arlt</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Krais</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Godschalk</surname><given-names>RW</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Pulmonary inflammation impacts on CYP1A1-mediated respiratory tract DNA damage induced by the carcinogenic Air pollutant benzo[a]pyrene</article-title>. <source>Toxicol Sci</source>. <year>2015</year>;<volume>146</volume>(<issue>2</issue>):<fpage>213</fpage>&#8211;<lpage>225</lpage>. doi:<pub-id pub-id-type="doi">10.1093/toxsci/kfv086</pub-id><pub-id pub-id-type="pmid">25911668</pub-id><pub-id pub-id-type="pmcid">PMC4517052</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maitra</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>P.</given-names></string-name></person-group><article-title>The potential role of transcription factor aryl hydrocarbon receptor in downregulation of hepatic cytochrome P-450 during sepsis</article-title>. <source>Int J Mol Med</source>. <year>2008</year>;<volume>21</volume>(<issue>4</issue>):<fpage>423</fpage>&#8211;<lpage>428</lpage>.<pub-id pub-id-type="pmid">18360687</pub-id><pub-id pub-id-type="pmcid">PMC2694573</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stading</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Swanson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>G</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Prenatal exposure to polycyclic aromatic hydrocarbons (PAHs) augments neonatal hyperoxic lung injury: role of cytochrome P450 (CYP)1A1, 1A2, and 1B1</article-title>. <source>Free Radic Biol Med</source>. <year>2024</year>;<volume>211</volume>:<fpage>35</fpage>&#8211;<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2023.12.001</pub-id><pub-id pub-id-type="pmid">38081439</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Q</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Identification of iron metabolism-related genes as diagnostic signatures in sepsis by blood transcriptomic analysis</article-title>. <source>Open Life Sci</source>. <year>2023</year>;<volume>18</volume>(<issue>1</issue>):<fpage>20220549</fpage>. doi:<pub-id pub-id-type="doi">10.1515/biol-2022-0549</pub-id><pub-id pub-id-type="pmid">36820206</pub-id><pub-id pub-id-type="pmcid">PMC9938542</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Identification and validation of a novel mitochondrion-related gene signature for diagnosis and immune infiltration in sepsis</article-title>. <source>Front Immunol</source>. <year>2023</year>;<volume>14</volume>:<fpage>1196306</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2023.1196306</pub-id><pub-id pub-id-type="pmid">37398680</pub-id><pub-id pub-id-type="pmcid">PMC10310918</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Damage effects of bisphenol A against sepsis induced acute lung injury</article-title>. <source>Gene</source>. <year>2023</year>;<volume>878</volume>:<fpage>147575</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.gene.2023.147575</pub-id><pub-id pub-id-type="pmid">37343733</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>P</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Human genetic factors associated with pneumonia risk, a cue for COVID-19 susceptibility</article-title>. <source>Infect Genet Evol</source>. <year>2022</year>;<volume>102</volume>:<fpage>105299</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.meegid.2022.105299</pub-id><pub-id pub-id-type="pmid">35545162</pub-id><pub-id pub-id-type="pmcid">PMC9080029</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Adil</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Rahman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Whitelaw</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>SARS-CoV-2 and the pandemic of COVID-19</article-title>. <source>Postgrad Med J</source>. <year>2021</year>;<volume>97</volume>(<issue>1144</issue>):<fpage>110</fpage>&#8211;<lpage>116</lpage>. doi:<pub-id pub-id-type="doi">10.1136/postgradmedj-2020-138386</pub-id><pub-id pub-id-type="pmid">32788312</pub-id><pub-id pub-id-type="pmcid">PMC10016996</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tanimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hirota</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fukazawa</surname><given-names>T</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Inhibiting SARS-CoV-2 infection in vitro by suppressing its receptor, angiotensin-converting enzyme 2, via aryl-hydrocarbon receptor signal</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>16629</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-021-96109-w</pub-id><pub-id pub-id-type="pmid">34404832</pub-id><pub-id pub-id-type="pmcid">PMC8371152</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stading</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Couroucli</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lingappan</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The role of cytochrome P450 (CYP) enzymes in hyperoxic lung injury</article-title>. <source>Expert Opin Drug Metab Toxicol</source>. <year>2021</year>;<volume>17</volume>(<issue>2</issue>):<fpage>171</fpage>&#8211;<lpage>178</lpage>. doi:<pub-id pub-id-type="doi">10.1080/17425255.2021.1853705</pub-id><pub-id pub-id-type="pmid">33215946</pub-id><pub-id pub-id-type="pmcid">PMC7864879</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Characterization of the lipidomic profile of human coronavirus-infected cells: implications for lipid metabolism remodeling upon coronavirus replication</article-title>. <source>Viruses</source>. <year>2019</year>;<volume>11</volume>(<issue>1</issue>):<fpage>73</fpage>. doi:<pub-id pub-id-type="doi">10.3390/v11010073</pub-id><pub-id pub-id-type="pmid">30654597</pub-id><pub-id pub-id-type="pmcid">PMC6357182</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ostor</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Nisar</surname><given-names>MK.</given-names></string-name></person-group><article-title>Interleukin-6 and cytochrome-P450, reason for concern?</article-title><source>Rheumatol Int</source>. <year>2012</year>;<volume>32</volume>(<issue>9</issue>):<fpage>2601</fpage>&#8211;<lpage>2604</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00296-012-2423-3</pub-id><pub-id pub-id-type="pmid">22451032</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The role of cytochrome P450 enzymes in COVID-19 pathogenesis and therapy</article-title>. <source>Front Pharmacol</source>. <year>2022</year>;<volume>13</volume>:<fpage>791922</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2022.791922</pub-id><pub-id pub-id-type="pmid">35185562</pub-id><pub-id pub-id-type="pmcid">PMC8847594</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Alam</surname><given-names>HB</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Peptidylarginine deiminases 2 mediates caspase-1-associated lethality in pseudomonas aeruginosa pneumonia-induced sepsis</article-title>. <source>J Infect Dis</source>. <year>2021</year>;<volume>223</volume>(<issue>6</issue>):<fpage>1093</fpage>&#8211;<lpage>1102</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiaa475</pub-id><pub-id pub-id-type="pmid">32729925</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ha</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Meliton</surname><given-names>LN</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Epigenetic mechanisms mediate cytochrome P450 1A1 expression and lung endothelial injury caused by MRSA in vitro and in vivo</article-title>. <source>FASEB J</source>. <year>2024</year>;<volume>38</volume>(<issue>22</issue>):<fpage>e70205</fpage>. doi:<pub-id pub-id-type="doi">10.1096/fj.202401812R</pub-id><pub-id pub-id-type="pmid">39588951</pub-id><pub-id pub-id-type="pmcid">PMC11590412</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rademacher</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Simanski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hesse</surname><given-names>B</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Staphylococcus epidermidis activates aryl hydrocarbon receptor signaling in human keratinocytes: implications for cutaneous defense</article-title>. <source>J Innate Immun</source>. <year>2019</year>;<volume>11</volume>(<issue>2</issue>):<fpage>125</fpage>&#8211;<lpage>135</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000492162</pub-id><pub-id pub-id-type="pmid">30176668</pub-id><pub-id pub-id-type="pmcid">PMC6738203</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moura-Alves</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fae</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Houthuys</surname><given-names>E</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Ahr sensing of bacterial pigments regulates antibacterial defence</article-title>. <source>Nature</source>. <year>2014</year>;<volume>512</volume>(<issue>7515</issue>):<fpage>387</fpage>&#8211;<lpage>392</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature13684</pub-id><pub-id pub-id-type="pmid">25119038</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maayah</surname><given-names>ZH</given-names></string-name>, <string-name name-style="western"><surname>El-Kadi</surname><given-names>AO.</given-names></string-name></person-group><article-title>The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy</article-title>. <source>Arch Toxicol</source>. <year>2016</year>;<volume>90</volume>(<issue>1</issue>):<fpage>119</fpage>&#8211;<lpage>136</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00204-015-1620-8</pub-id><pub-id pub-id-type="pmid">26525395</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baglole</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Maggirwar</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Gasiewicz</surname><given-names>TA</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The aryl hydrocarbon receptor attenuates tobacco smoke-induced cyclooxygenase-2 and prostaglandin production in lung fibroblasts through regulation of the NF-kappaB family member RelB</article-title>. <source>J Biol Chem</source>. <year>2008</year>;<volume>283</volume>(<issue>43</issue>):<fpage>28944</fpage>&#8211;<lpage>28957</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M800685200</pub-id><pub-id pub-id-type="pmid">18697742</pub-id><pub-id pub-id-type="pmcid">PMC2570856</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shivanna</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Functional deficiency of aryl hydrocarbon receptor augments oxygen toxicity-induced alveolar simplification in newborn mice</article-title>. <source>Toxicol Appl Pharmacol</source>. <year>2013</year>;<volume>267</volume>(<issue>3</issue>):<fpage>209</fpage>&#8211;<lpage>217</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.taap.2013.01.003</pub-id><pub-id pub-id-type="pmid">23337360</pub-id><pub-id pub-id-type="pmcid">PMC3582791</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Aryl hydrocarbon receptor is necessary to protect fetal human pulmonary microvascular endothelial cells against hyperoxic injury: mechanistic roles of antioxidant enzymes and RelB</article-title>. <source>Toxicol Appl Pharmacol</source>. <year>2015</year>;<volume>286</volume>(<issue>2</issue>):<fpage>92</fpage>&#8211;<lpage>101</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.taap.2015.03.023</pub-id><pub-id pub-id-type="pmid">25831079</pub-id><pub-id pub-id-type="pmcid">PMC4458211</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vogel</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Leung</surname><given-names>PS</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cross-talk between aryl hydrocarbon receptor and the inflammatory response: a role for nuclear factor-kappaB</article-title>. <source>J Biol Chem</source>. <year>2014</year>;<volume>289</volume>(<issue>3</issue>):<fpage>1866</fpage>&#8211;<lpage>1875</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M113.505578</pub-id><pub-id pub-id-type="pmid">24302727</pub-id><pub-id pub-id-type="pmcid">PMC3894361</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shivanna</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Welty</surname><given-names>SE</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Omeprazole attenuates hyperoxic injury in H441 cells via the aryl hydrocarbon receptor</article-title>. <source>Free Radic Biol Med</source>. <year>2011</year>;<volume>51</volume>(<issue>10</issue>):<fpage>1910</fpage>&#8211;<lpage>1917</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.08.013</pub-id><pub-id pub-id-type="pmid">21906671</pub-id><pub-id pub-id-type="pmcid">PMC3901644</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ke</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rabson</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Germino</surname><given-names>JF</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide</article-title>. <source>J Biol Chem</source>. <year>2001</year>;<volume>276</volume>(<issue>43</issue>):<fpage>39638</fpage>&#8211;<lpage>39644</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M106286200</pub-id><pub-id pub-id-type="pmid">11470802</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kourylko</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Fradette</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Arcand</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Modulation of CYP1A2 and CYP3A6 catalytic activities by serum from rabbits with a turpentine-induced inflammatory reaction and interleukin 6</article-title>. <source>Drug Metab Dispos</source>. <year>2006</year>;<volume>34</volume>(<issue>1</issue>):<fpage>27</fpage>&#8211;<lpage>35</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.105.006528</pub-id><pub-id pub-id-type="pmid">16204464</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>N</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Inhibition of nuclear factor-kappaB signal by pyrrolidine dithiocarbamate alleviates lipopolysaccharide-induced acute lung injury</article-title>. <source>Oncotarget</source>. <year>2017</year>;<volume>8</volume>(<issue>29</issue>):<fpage>47296</fpage>&#8211;<lpage>47304</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.17624</pub-id><pub-id pub-id-type="pmid">28521300</pub-id><pub-id pub-id-type="pmcid">PMC5564565</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xun</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Advanced oxidation protein products downregulate CYP1A2 and CYP3A4 expression and activity via the NF-kappaB-mediated signaling pathway in vitro and in vivo</article-title>. <source>Lab Invest</source>. <year>2021</year>;<volume>101</volume>(<issue>9</issue>):<fpage>1197</fpage>&#8211;<lpage>1209</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41374-021-00610-9</pub-id><pub-id pub-id-type="pmid">34031539</pub-id><pub-id pub-id-type="pmcid">PMC8367815</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Abate</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>George</surname><given-names>AG</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Maturational differences in lung NF-kappaB activation and their role in tolerance to hyperoxia</article-title>. <source>J Clin Invest</source>. <year>2004</year>;<volume>114</volume>(<issue>5</issue>):<fpage>669</fpage>&#8211;<lpage>678</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI200419300</pub-id><pub-id pub-id-type="pmid">15343385</pub-id><pub-id pub-id-type="pmcid">PMC514581</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lingappan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Sex-specific differences in neonatal hyperoxic lung injury</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <year>2016</year>;<volume>311</volume>(<issue>2</issue>):<fpage>L481</fpage>&#8211;<lpage>L493</lpage>. doi:<pub-id pub-id-type="doi">10.1152/ajplung.00047.2016</pub-id><pub-id pub-id-type="pmid">27343189</pub-id><pub-id pub-id-type="pmcid">PMC5504425</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bohuslav</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kravchenko</surname><given-names>VV</given-names></string-name>, <string-name name-style="western"><surname>Parry</surname><given-names>GC</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Regulation of an essential innate immune response by the p50 subunit of NF-kappaB</article-title>. <source>J Clin Invest</source>. <year>1998</year>;<volume>102</volume>(<issue>9</issue>):<fpage>1645</fpage>&#8211;<lpage>1652</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI3877</pub-id><pub-id pub-id-type="pmid">9802878</pub-id><pub-id pub-id-type="pmcid">PMC509112</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Udalova</surname><given-names>IA</given-names></string-name>, <string-name name-style="western"><surname>Richardson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Denys</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region</article-title>. <source>Mol Cell Biol</source>. <year>2000</year>;<volume>20</volume>(<issue>24</issue>):<fpage>9113</fpage>&#8211;<lpage>9119</lpage>. doi:<pub-id pub-id-type="doi">10.1128/MCB.20.24.9113-9119.2000</pub-id><pub-id pub-id-type="pmid">11094063</pub-id><pub-id pub-id-type="pmcid">PMC102169</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Son</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>HT</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Reactive oxygen species in the activation of MAP kinases</article-title>. <source>Methods Enzymol</source>. <year>2013</year>;<volume>528</volume>:<fpage>27</fpage>&#8211;<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1016/B978-0-12-405881-1.00002-1</pub-id><pub-id pub-id-type="pmid">23849857</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>MNK as a potential pharmacological target for suppressing LPS-induced acute lung injury in mice</article-title>. <source>Biochem Pharmacol</source>. <year>2021</year>;<volume>186</volume>:<fpage>114499</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bcp.2021.114499</pub-id><pub-id pub-id-type="pmid">33675774</pub-id><pub-id pub-id-type="pmcid">PMC7957947</pub-id></mixed-citation></ref><ref id="CIT0075"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>XX</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>LJ</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Eurotium cristatum fermented loose dark Tea ameliorates cigarette smoke-induced lung injury by MAPK pathway and enhances hepatic metabolic detoxification by PXR/AhR pathway in mice</article-title>. <source>Oxid Med Cell Longev</source>. <year>2021</year>;<volume>2021</volume>:<fpage>6635080</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2021/6635080</pub-id><pub-id pub-id-type="pmid">33777316</pub-id><pub-id pub-id-type="pmcid">PMC7972846</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lingappan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Srinivasan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Analysis of the transcriptome in hyperoxic lung injury and sex-specific alterations in gene expression</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>7</issue>):<fpage>e101581</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0101581</pub-id><pub-id pub-id-type="pmid">25003466</pub-id><pub-id pub-id-type="pmcid">PMC4086819</pub-id></mixed-citation></ref><ref id="CIT0077"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reddy</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Potteti</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Mariani</surname><given-names>TJ</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Conditional deletion of Nrf2 in airway epithelium exacerbates acute lung injury and impairs the resolution of inflammation</article-title>. <source>Am J Respir Cell Mol Biol</source>. <year>2011</year>;<volume>45</volume>(<issue>6</issue>):<fpage>1161</fpage>&#8211;<lpage>1168</lpage>. doi:<pub-id pub-id-type="doi">10.1165/rcmb.2011-0144OC</pub-id><pub-id pub-id-type="pmid">21659655</pub-id><pub-id pub-id-type="pmcid">PMC3262666</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Callaway</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Oxygen-mediated lung injury in mice lacking the gene for NRF2: rescue with the cytochrome P4501A-inducer, beta-naphthoflavone (BNF), and differential sex-specific effects</article-title>. <source>Free Radic Biol Med</source>. <year>2020</year>;<volume>160</volume>:<fpage>208</fpage>&#8211;<lpage>218</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.07.027</pub-id><pub-id pub-id-type="pmid">32791187</pub-id><pub-id pub-id-type="pmcid">PMC7704914</pub-id></mixed-citation></ref><ref id="CIT0079"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Takei</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hashimoto-Hachiya</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Takahara</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cynaropicrin attenuates UVB-induced oxidative stress via the AhR-Nrf2-Nqo1 pathway</article-title>. <source>Toxicol Lett</source>. <year>2015</year>;<volume>234</volume>(<issue>2</issue>):<fpage>74</fpage>&#8211;<lpage>80</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.toxlet.2015.02.007</pub-id><pub-id pub-id-type="pmid">25680693</pub-id></mixed-citation></ref><ref id="CIT0080"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Furue</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Uchi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mitoma</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Antioxidants for healthy skin: The emerging role of aryl hydrocarbon receptors and nuclear factor-erythroid 2-related factor-2</article-title>. <source>Nutrients</source>. <year>2017</year>;<volume>9</volume>(<issue>3</issue>):<fpage>223</fpage>. doi:<pub-id pub-id-type="doi">10.3390/nu9030223</pub-id><pub-id pub-id-type="pmid">28273792</pub-id><pub-id pub-id-type="pmcid">PMC5372886</pub-id></mixed-citation></ref><ref id="CIT0081"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weng</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Nrf2-Keap1-ARE-NQO1 signaling attenuates hyperoxia-induced lung cell injury by inhibiting apoptosis</article-title>. <source>Mol Med Rep</source>. <year>2021</year>;<volume>23</volume>(<issue>3</issue>):<fpage>221</fpage>. doi:<pub-id pub-id-type="doi">10.3892/mmr.2021.11860</pub-id><pub-id pub-id-type="pmid">33495821</pub-id></mixed-citation></ref><ref id="CIT0082"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Burke</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>GD</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Role of human NADPH quinone oxidoreductase (NQO1) in oxygen-mediated cellular injury and oxidative DNA damage in human pulmonary cells</article-title>. <source>Oxid Med Cell Longev</source>. <year>2021</year>;<volume>2021</volume>:<fpage>5544600</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2021/5544600</pub-id><pub-id pub-id-type="pmid">34691356</pub-id><pub-id pub-id-type="pmcid">PMC8536466</pub-id></mixed-citation></ref><ref id="CIT0083"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Veith</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Bou Aram</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Mice lacking the cytochrome P450 1B1 gene Are less susceptible to hyperoxic lung injury than wild type</article-title>. <source>Toxicol Sci</source>. <year>2018</year>;<volume>165</volume>(<issue>2</issue>):<fpage>462</fpage>&#8211;<lpage>474</lpage>. doi:<pub-id pub-id-type="doi">10.1093/toxsci/kfy154</pub-id><pub-id pub-id-type="pmid">29939353</pub-id><pub-id pub-id-type="pmcid">PMC6154276</pub-id></mixed-citation></ref><ref id="CIT0084"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hankinson</surname><given-names>O.</given-names></string-name></person-group><article-title>The role of AHR-inducible cytochrome P450s in metabolism of polyunsaturated fatty acids</article-title>. <source>Drug Metab Rev</source>. <year>2016</year>;<volume>48</volume>(<issue>3</issue>):<fpage>342</fpage>&#8211;<lpage>350</lpage>. doi:<pub-id pub-id-type="doi">10.1080/03602532.2016.1197240</pub-id><pub-id pub-id-type="pmid">27358009</pub-id><pub-id pub-id-type="pmcid">PMC5026385</pub-id></mixed-citation></ref><ref id="CIT0085"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shivanna</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Maity</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Gene expression profiling identifies cell proliferation and inflammation as the predominant pathways regulated by aryl hydrocarbon receptor in primary human fetal lung cells exposed to hyperoxia</article-title>. <source>Toxicol Sci</source>. <year>2016</year>;<volume>152</volume>(<issue>1</issue>):<fpage>155</fpage>&#8211;<lpage>168</lpage>. doi:<pub-id pub-id-type="doi">10.1093/toxsci/kfw071</pub-id><pub-id pub-id-type="pmid">27103661</pub-id><pub-id pub-id-type="pmcid">PMC4922543</pub-id></mixed-citation></ref><ref id="CIT0086"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shivanna</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Omeprazole attenuates pulmonary aryl hydrocarbon receptor activation and potentiates hyperoxia-induced developmental lung injury in newborn mice</article-title>. <source>Toxicol Sci</source>. <year>2015</year>;<volume>148</volume>(<issue>1</issue>):<fpage>276</fpage>&#8211;<lpage>287</lpage>. doi:<pub-id pub-id-type="doi">10.1093/toxsci/kfv183</pub-id><pub-id pub-id-type="pmid">26272953</pub-id><pub-id pub-id-type="pmcid">PMC4635634</pub-id></mixed-citation></ref><ref id="CIT0087"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nishimura</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yoshitsugu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Naito</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR</article-title>. <source>Yakugaku Zasshi</source>. <year>2002</year>;<volume>122</volume>(<issue>5</issue>):<fpage>339</fpage>&#8211;<lpage>361</lpage>. doi:<pub-id pub-id-type="doi">10.1248/yakushi.122.339</pub-id><pub-id pub-id-type="pmid">12040753</pub-id></mixed-citation></ref><ref id="CIT0088"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Posti</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Leinonen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tetri</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Modulation of murine phenobarbital-inducible CYP2A5, CYP2B10 and CYP1A enzymes by inhibitors of protein kinases and phosphatases</article-title>. <source>Eur J Biochem</source>. <year>1999</year>;<volume>264</volume>(<issue>1</issue>):<fpage>19</fpage>&#8211;<lpage>26</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1432-1327.1999.00539.x</pub-id><pub-id pub-id-type="pmid">10447669</pub-id></mixed-citation></ref><ref id="CIT0089"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Paramahamsa</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Leflunomide induces pulmonary and hepatic CYP1A enzymes via aryl hydrocarbon receptor</article-title>. <source>Drug Metab Dispos</source>. <year>2015</year>;<volume>43</volume>(<issue>12</issue>):<fpage>1966</fpage>&#8211;<lpage>1970</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.115.066084</pub-id><pub-id pub-id-type="pmid">26417045</pub-id><pub-id pub-id-type="pmcid">PMC4658494</pub-id></mixed-citation></ref><ref id="CIT0090"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>SF.</given-names></string-name></person-group><article-title>Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development</article-title>. <source>Curr Med Chem</source>. <year>2009</year>;<volume>16</volume>(<issue>31</issue>):<fpage>4066</fpage>&#8211;<lpage>4218</lpage>. doi:<pub-id pub-id-type="doi">10.2174/092986709789378198</pub-id><pub-id pub-id-type="pmid">19754423</pub-id></mixed-citation></ref><ref id="CIT0091"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anwar-Mohamed</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>El-Sherbeni</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Hamdy</surname><given-names>DA</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Ketoconazole stereoisomers differentially induce cytochrome P450 1A1 between human hepatoma HepG2 and mouse hepatoma Hepa1c1c7 cells</article-title>. <source>J Pharm Sci</source>. <year>2016</year>;<volume>105</volume>(<issue>3</issue>):<fpage>1318</fpage>&#8211;<lpage>1326</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.xphs.2015.12.009</pub-id><pub-id pub-id-type="pmid">26886340</pub-id></mixed-citation></ref><ref id="CIT0092"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kapelyukh</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Henderson</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Scheer</surname><given-names>N</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Defining the contribution of CYP1A1 and CYP1A2 to drug metabolism using humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 knockout mice</article-title>. <source>Drug Metab Dispos</source>. <year>2019</year>;<volume>47</volume>(<issue>8</issue>):<fpage>907</fpage>&#8211;<lpage>918</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.119.087718</pub-id><pub-id pub-id-type="pmid">31147315</pub-id><pub-id pub-id-type="pmcid">PMC6657216</pub-id></mixed-citation></ref><ref id="CIT0093"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jacob</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hartz</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Potin</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Aryl hydrocarbon receptor-dependent upregulation of Cyp1b1 by TCDD and diesel exhaust particles in rat brain microvessels</article-title>. <source>Fluids Barriers CNS</source>. <year>2011</year>;<volume>8</volume>:<fpage>23</fpage>. doi:<pub-id pub-id-type="doi">10.1186/2045-8118-8-23</pub-id><pub-id pub-id-type="pmid">21867498</pub-id><pub-id pub-id-type="pmcid">PMC3180256</pub-id></mixed-citation></ref><ref id="CIT0094"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>John</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Divi</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Keshava</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>CYP1A1 and CYP1B1 gene expression and DNA adduct formation in normal human mammary epithelial cells exposed to benzo[a]pyrene in the absence or presence of chlorophyllin</article-title>. <source>Cancer Lett</source>. <year>2010</year>;<volume>292</volume>(<issue>2</issue>):<fpage>254</fpage>&#8211;<lpage>260</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.canlet.2009.12.008</pub-id><pub-id pub-id-type="pmid">20163913</pub-id><pub-id pub-id-type="pmcid">PMC3475201</pub-id></mixed-citation></ref><ref id="CIT0095"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Couroucli</surname><given-names>XI</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Prenatal administration of the cytochrome P4501A inducer, beta-naphthoflavone (BNF), attenuates hyperoxic lung injury in newborn mice: implications for bronchopulmonary dysplasia (BPD) in premature infants</article-title>. <source>Toxicol Appl Pharmacol</source>. <year>2011</year>;<volume>256</volume>(<issue>2</issue>):<fpage>83</fpage>&#8211;<lpage>94</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.taap.2011.06.018</pub-id><pub-id pub-id-type="pmid">21745492</pub-id><pub-id pub-id-type="pmcid">PMC3196339</pub-id></mixed-citation></ref><ref id="CIT0096"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Juvonen</surname><given-names>RO</given-names></string-name>, <string-name name-style="western"><surname>Jokinen</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Javaid</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Inhibition of human CYP1 enzymes by a classical inhibitor alpha-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study</article-title>. <source>Chem Biol Drug Des</source>. <year>2020</year>;<volume>95</volume>(<issue>5</issue>):<fpage>520</fpage>&#8211;<lpage>533</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cbdd.13669</pub-id><pub-id pub-id-type="pmid">32060993</pub-id></mixed-citation></ref><ref id="CIT0097"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kuo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>TK.</given-names></string-name></person-group><article-title>Effect of ginkgo biloba extract on rat hepatic microsomal CYP1A activity: role of ginkgolides, bilobalide, and flavonols</article-title>. <source>Can J Physiol Pharmacol</source>. <year>2004</year>;<volume>82</volume>(<issue>1</issue>):<fpage>57</fpage>&#8211;<lpage>64</lpage>. doi:<pub-id pub-id-type="doi">10.1139/y03-133</pub-id><pub-id pub-id-type="pmid">15052306</pub-id></mixed-citation></ref><ref id="CIT0098"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Forno</surname><given-names>E.</given-names></string-name></person-group><article-title>Exercise and lifestyle changes in pediatric asthma</article-title>. <source>Curr Opin Pulm Med</source>. <year>2020</year>;<volume>26</volume>(<issue>1</issue>):<fpage>103</fpage>&#8211;<lpage>111</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MCP.0000000000000636</pub-id><pub-id pub-id-type="pmid">31652153</pub-id><pub-id pub-id-type="pmcid">PMC7094764</pub-id></mixed-citation></ref><ref id="CIT0099"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>New pulmonary rehabilitation exercise for pulmonary fibrosis to improve the pulmonary function and quality of life of patients with idiopathic pulmonary fibrosis: a randomized control trial</article-title>. <source>Ann Palliat Med</source>. <year>2021</year>;<volume>10</volume>(<issue>7</issue>):<fpage>7289</fpage>&#8211;<lpage>7297</lpage>. doi:<pub-id pub-id-type="doi">10.21037/apm-21-71</pub-id><pub-id pub-id-type="pmid">34353031</pub-id></mixed-citation></ref><ref id="CIT0100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fiorentino</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Esquinas</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Annunziata</surname><given-names>A.</given-names></string-name></person-group><article-title>Exercise and chronic obstructive pulmonary disease (COPD)</article-title>. <source>Adv Exp Med Biol</source>. <year>2020</year>;<volume>1228</volume>:<fpage>355</fpage>&#8211;<lpage>368</lpage>. doi:<pub-id pub-id-type="doi">10.1007/978-981-15-1792-1_24</pub-id><pub-id pub-id-type="pmid">32342470</pub-id></mixed-citation></ref><ref id="CIT0101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Piatkowski</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Day</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Weiner</surname><given-names>M.</given-names></string-name></person-group><article-title>Increased renal drug metabolism in treadmill-exercised fischer-344 male rats</article-title>. <source>Drug Metab Dispos</source>. <year>1993</year>;<volume>21</volume>(<issue>3</issue>):<fpage>474</fpage>&#8211;<lpage>479</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0090-9556(25)07403-3</pub-id><pub-id pub-id-type="pmid">8100504</pub-id></mixed-citation></ref><ref id="CIT0102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>So</surname><given-names>WY</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SH</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Expression profiles of cytochrome P450s following swimming exercise in aging rats</article-title>. <source>J Mens Health</source>. <year>2017</year>;<volume>13</volume>(<issue>2</issue>):<fpage>E25</fpage>&#8211;<lpage>E33</lpage>.</mixed-citation></ref><ref id="CIT0103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vistisen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Poulsen</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Loft</surname><given-names>S.</given-names></string-name></person-group><article-title>Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine</article-title>. <source>Carcinogenesis</source>. <year>1992</year>;<volume>13</volume>(<issue>9</issue>):<fpage>1561</fpage>&#8211;<lpage>1568</lpage>. doi:<pub-id pub-id-type="doi">10.1093/carcin/13.9.1561</pub-id><pub-id pub-id-type="pmid">1394840</pub-id></mixed-citation></ref><ref id="CIT0104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Knudsen</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Bertholdt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gudiksen</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Skeletal muscle interleukin-6 regulates hepatic cytochrome P450 expression: effects of 16-week high-Fat diet and exercise</article-title>. <source>Toxicol Sci</source>. <year>2018</year>;<volume>162</volume>(<issue>1</issue>):<fpage>309</fpage>&#8211;<lpage>317</lpage>. doi:<pub-id pub-id-type="doi">10.1093/toxsci/kfx258</pub-id><pub-id pub-id-type="pmid">29177473</pub-id></mixed-citation></ref><ref id="CIT0105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lingappan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Mice deficient in the gene for cytochrome P450 (CYP)1A1 are more susceptible than wild-type to hyperoxic lung injury: evidence for protective role of CYP1A1 against oxidative stress</article-title>. <source>Toxicol Sci</source>. <year>2014</year>;<volume>141</volume>(<issue>1</issue>):<fpage>68</fpage>&#8211;<lpage>77</lpage>. doi:<pub-id pub-id-type="doi">10.1093/toxsci/kfu106</pub-id><pub-id pub-id-type="pmid">24893714</pub-id><pub-id pub-id-type="pmcid">PMC4200035</pub-id></mixed-citation></ref><ref id="CIT0106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Van Marter</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Leviton</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kuban</surname><given-names>KC</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia</article-title>. <source>Pediatrics</source>. <year>1990</year>;<volume>86</volume>(<issue>3</issue>):<fpage>331</fpage>&#8211;<lpage>336</lpage>. doi:<pub-id pub-id-type="doi">10.1542/peds.86.3.331</pub-id><pub-id pub-id-type="pmid">2201940</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>